var title_f2_46_2784="Contents: Brain and nerves";
var content_f2_46_2784=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Brain and nerves",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Brain and nerves",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Altered mental status",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11155\">",
"           Patient information: Delirium (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/54/8034\">",
"           Patient information: Delirium (confusion) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Amyotrophic lateral sclerosis (ALS)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21041\">",
"           Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bell's palsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/13/41168\">",
"           Patient information: Bell's palsy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32977\">",
"           Patient information: Bell's palsy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Brain tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6690\">",
"           Patient information: Astrocytoma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/48/9986\">",
"           Patient information: Brain cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19650\">",
"           Patient information: Brain metastases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/28/22978\">",
"           Patient information: Glioblastoma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/52/8004\">",
"           Patient information: High-grade glioma in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/15/5362\">",
"           Patient information: Meningioma (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36515\">",
"           Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Carotid artery disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23635\">",
"           Patient information: Atherosclerosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12512\">",
"           Patient information: Carotid artery disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Carpal tunnel",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/49/18194\">",
"           Patient information: Carpal tunnel syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23746\">",
"           Patient information: Chronic pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/6/11363\">",
"           Patient information: Narcotic pain medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8867\">",
"           Patient information: Neuropathic pain (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37905\">",
"           Patient information: Coma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Creutzfeldt-Jakob disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25378\">",
"           Patient information: Creutzfeldt-Jakob disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetic neuropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21587\">",
"           Patient information: Diabetic neuropathy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43618\">",
"           Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20208\">",
"           Patient information: Nerve damage caused by diabetes (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Encephalitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/50/18209\">",
"           Patient information: Encephalitis in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Guillain-Barr&eacute; syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/37/37457\">",
"           Patient information: Guillain-Barr������ syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Head injury",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8947\">",
"           Patient information: Closed head injury (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/12/22722\">",
"           Patient information: Concussion (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/44/14020\">",
"           Patient information: Head injury in children and adolescents (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/45/40658\">",
"           Patient information: Head injury in children and adolescents (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20945\">",
"           Patient information: Postconcussion syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/14/24801\">",
"           Patient information: Subdural hematoma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Headaches",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/31/3570\">",
"           Patient information: Headache (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16179\">",
"           Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/59/42931\">",
"           Patient information: Headache treatment in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27090\">",
"           Patient information: Headaches in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/57/35731\">",
"           Patient information: Migraine headaches in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/9/33938\">",
"           Patient information: Migraine headaches in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Huntington disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/56/27521\">",
"           Patient information: Huntington disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intracranial hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/51/38706\">",
"           Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Memory loss and dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14934\">",
"           Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/14/31970\">",
"           Patient information: Dementia (including Alzheimer disease) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35009\">",
"           Patient information: Dementia with HIV (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/3/18482\">",
"           Patient information: Dementia with Lewy bodies (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/3/31793\">",
"           Patient information: Evaluating memory and thinking problems (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/20/2370\">",
"           Patient information: Mild cognitive impairment (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/22/32098\">",
"           Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Meningitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/35/16946\">",
"           Patient information: Aseptic meningitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31762\">",
"           Patient information: Bacterial meningitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36962\">",
"           Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1796\">",
"           Patient information: Meningitis in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/43/3763\">",
"           Patient information: Meningitis in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/34/28194\">",
"           Patient information: Viral meningitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple sclerosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40447\">",
"           Patient information: Multiple sclerosis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17138\">",
"           Patient information: Multiple sclerosis in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10722\">",
"           Patient information: Optic neuritis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myasthenia gravis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14562\">",
"           Patient information: Myasthenia gravis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nerve and muscle disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/59/24497\">",
"           Patient information: Charcot-Marie-Tooth disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/57/3986\">",
"           Patient information: Friedreich ataxia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34001\">",
"           Patient information: Muscular dystrophy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2754\">",
"           Patient information: Myoclonus (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32276\">",
"           Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/10/33954\">",
"           Patient information: Periodic paralysis syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/8/21633\">",
"           Patient information: Spasmodic dysphonia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1409\">",
"           Patient information: Trigeminal neuralgia (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parkinson disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/8/34947\">",
"           Patient information: Medicines for Parkinson disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13954\">",
"           Patient information: Parkinson disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/4/5188\">",
"           Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28449\">",
"           Patient information: Parkinson disease treatment options ��������� education, support, and therapy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/63/30708\">",
"           Patient information: Parkinson disease treatment options ��������� medications (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34913\">",
"           Patient information: Tremor (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/14/13538\">",
"           Patient information: Tremor (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Seizures and epilepsy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18434\">",
"           Patient information: EEG (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/5/30802\">",
"           Patient information: Epilepsy and pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/40/43650\">",
"           Patient information: Epilepsy in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39473\">",
"           Patient information: Febrile seizures (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11586\">",
"           Patient information: Febrile seizures (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28546\">",
"           Patient information: Seizures (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34229\">",
"           Patient information: Seizures in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/419\">",
"           Patient information: Seizures in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19540\">",
"           Patient information: Treatment of seizures in children (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Spinal cord injury",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11522\">",
"           Patient information: Cauda equina syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/18/43297\">",
"           Patient information: Central spinal cord syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/0/15363\">",
"           Patient information: Neck fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/53/27475\">",
"           Patient information: Paraplegia and quadriplegia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/8/32898\">",
"           Patient information: Radiculopathy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Spinal stenosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40642\">",
"           Patient information: Spinal stenosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stroke",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/61/30674\">",
"           Patient information: Aphasia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26274\">",
"           Patient information: Arteriovenous malformations in the brain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/5/23635\">",
"           Patient information: Atherosclerosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5394\">",
"           Patient information: Brain aneurysm (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12512\">",
"           Patient information: Carotid artery disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/23/26994\">",
"           Patient information: Dysarthria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/34/22050\">",
"           Patient information: Hemorrhagic stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/63/8180\">",
"           Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/53/19286\">",
"           Patient information: Ischemic stroke treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/40/39554\">",
"           Patient information: Lowering the risk of having another stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36435\">",
"           Patient information: Medicines after an ischemic stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/45/3795\">",
"           Patient information: Recovery after stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/55/24435\">",
"           Patient information: Stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/37/38484\">",
"           Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/19/30002\">",
"           Patient information: Subarachnoid hemorrhage (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/18/20772\">",
"           Patient information: Transient ischemic attack (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35170\">",
"           Patient information: Transient ischemic attack (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18434\">",
"           Patient information: EEG (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/23/44402\">",
"           Patient information: Lumbar puncture (spinal tap) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tremor",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34913\">",
"           Patient information: Tremor (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/14/13538\">",
"           Patient information: Tremor (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vertigo",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41460\">",
"           Patient information: Dizziness and vertigo (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/59/41905\">",
"           Patient information: Vertigo (a type of dizziness) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-CFE95024C5-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_46_2784=[""].join("\n");
var outline_f2_46_2784=null;
var title_f2_46_2785="RB ILD CT II";
var content_f2_46_2785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory bronchiolitis-associated interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT scan (1.5 mm thick section) in a 35-year-old woman with heavy smoking history and progressive dyspnea with exertion. Extensive ground-glass opacities are seen more clearly than on conventional CT scan (5 mm thick section).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2785=[""].join("\n");
var outline_f2_46_2785=null;
var title_f2_46_2786="Wrist osteoarthritis";
var content_f2_46_2786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wrist osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The articular cartilage between the radius and the scaphoid is narrowed. This finding is characteristic of osteoarthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal wrist radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anterior-posterior view of the wrist is normal. The width of the articular cartilage is 2 mm and is identical to the width of the intercarpal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2786=[""].join("\n");
var outline_f2_46_2786=null;
var title_f2_46_2787="Sulconazole: Drug information";
var content_f2_46_2787=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/37/31315?source=see_link\">",
"    see \"Sulconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exelderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Exelderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Tinea infection",
"     </b>",
"     : Topical: Apply a small amount to the affected area and gently massage once or twice daily (tinea pedis apply twice daily) for 3 weeks (tinea cruris, tinea corporis, tinea versicolor) to 4 weeks (tinea pedis).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelderm&reg;: 1% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exelderm&reg;: 1% (30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial fungal infections of the skin, including tinea cruris (jock itch), tinea corporis (ringworm), tinea versicolor, and tinea pedis (athlete's foot, cream only)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, stinging, redness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulconazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F223689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies with large doses administered orally. Systemic absorption is limited following topical administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16571278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sulconazole is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sulconazole to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F223667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Exelderm External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 g): $102.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Exelderm External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 mL): $102.03",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Exelderm (GB, IE, IT, KP, TW);",
"     </li>",
"     <li>",
"      Fulcol (EC);",
"     </li>",
"     <li>",
"      Genfuxen (TW);",
"     </li>",
"     <li>",
"      Minot (AR);",
"     </li>",
"     <li>",
"      Myk (FR);",
"     </li>",
"     <li>",
"      Myk 1 (BE, LU, NL);",
"     </li>",
"     <li>",
"      Suldisyn (GR);",
"     </li>",
"     <li>",
"      Zynoc (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Substituted imidazole derivative which inhibits metabolic reactions necessary for the synthesis of ergosterol, an essential membrane component. The end result is usually fungistatic; however, sulconazole may act as a fungicide in",
"     <i>",
"      Candida albicans",
"     </i>",
"     and",
"     <i>",
"      Candida parapsilosis",
"     </i>",
"     during certain growth phases.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: ~8.7% percutaneously",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9956 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2787=[""].join("\n");
var outline_f2_46_2787=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223673\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223692\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223674\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223675\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223662\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223650\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223663\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223690\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223666\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223654\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223689\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223658\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223659\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079780\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223676\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16571278\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223667\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223668\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223665\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9956|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/37/31315?source=related_link\">",
"      Sulconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_46_2788="Necrotic adenoca colon Endosc";
var content_f2_46_2788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Necrotic adenocarcinoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy showing necrotic colonic lesions that usually suggest an advanced stage of malignancy. Panel A: severe tissue destruction has led to necrosis and bleeding; Panel B: the longstanding tumor has extended deeply into the mucosa and become necrotic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2788=[""].join("\n");
var outline_f2_46_2788=null;
var title_f2_46_2789="Pleural effusion lung TPL PA";
var content_f2_46_2789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural effusion after lung transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph taken on the 10th postoperative day in a patient who received a left, single-lung transplant. A left, predominantly subpulmonic pleural effusion of small to moderate size is present (arrow). The effusion resolved by the next week. Surveillance transbronchial biopsy revealed minimal acute rejection that did not require treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc A Judson, MD",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2789=[""].join("\n");
var outline_f2_46_2789=null;
var title_f2_46_2790="Well diff squamous CA Light";
var content_f2_46_2790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well-differentiated squamous cell carcinoma of the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph of a well differentiated squamous cell tumor with well-defined intercellular bridges and keratin pearls (black arrows). Nuclear pleomorphism is mild to moderate, and the mitotic rate is low.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2790=[""].join("\n");
var outline_f2_46_2790=null;
var title_f2_46_2791="Pathobiology of Burkitt lymphoma";
var content_f2_46_2791=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathobiology of Burkitt lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Jennifer R Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2791/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/46/2791/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burkitt lymphoma (BL) is a highly aggressive B cell neoplasm characterized by the translocation and deregulation of the c-MYC gene on chromosome 8. Three distinct clinical forms of BL are recognized: endemic, sporadic, and immunodeficiency-associated. Although they are histologically identical and have similar clinical behavior, there are differences in epidemiology, clinical presentation, and genetic features between the three forms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BL and Burkitt leukemia (FAB L3 acute lymphoblastic leukemia) are classified as different manifestations of the same disease in the 2008 World Health Organization (WHO) classification of hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/1\">",
"     1",
"    </a>",
"    ]. The WHO classification also recognizes the existence of tumors with features intermediate between BL and diffuse large B cell lymphoma, which remain difficult diagnostic challenges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of BL will be discussed here. Information regarding the diagnosis and treatment of BL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;BL is derived from germinal or post-germinal center B cells. The germinal or post-germinal center ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin genes (IgV), which serve as a marker of germinal center transit, as well as the tumor cell immunophenotype. Some studies have demonstrated ongoing somatic mutation, a process that is normally restricted to germinal center B cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Other genetic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different clinical subtypes of BL (ie, endemic, nonendemic, and immunodeficiency-related) likely arise from B cells at different stages of development. Specifically, Epstein Barr virus (EBV)-negative BLs show a low level of somatic hypermutation of their variable region heavy chain genes and no signs of antigen selection, whereas EBV-positive (generally endemic or AIDS-related) BLs have significantly higher levels of somatic hypermutation and evidence of antigen selection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/2\">",
"     2",
"    </a>",
"    ]. These findings suggest that EBV-negative BL may arise from an early centroblast, while EBV-positive BL may arise from a memory B cell or late germinal center B cell. This difference in cell of origin may also relate to the observed difference in c-MYC translocation breakpoints described below. Despite these differences, these clinical subtypes have many similarities in gene expression suggesting a common pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Chromosomal translocations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of BL is dependent upon the constitutive expression of the c-MYC proto-oncogene located at chromosome 8q24, which encodes the MYC protein transcription factor. This transcription factor modulates the expression of target genes that regulate many cellular processes, including cell growth, division, death, metabolism, adhesion, and motility [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Cells can generate high levels of c-MYC protein through various mechanisms as described in the sections below.",
"   </p>",
"   <p>",
"    The vast majority of tumors have c-MYC rearrangements. However, in the 2008 WHO classification of lymphoid neoplasms, the diagnosis of BL is permitted in the absence of c-MYC rearrangement if all other morphologic, immunophenotypic, and genetic findings support the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/1\">",
"     1",
"    </a>",
"    ]. This allowance reflects the recognition that up to 5 percent of tumors with features otherwise typical of BL lack c-MYC rearrangements.",
"   </p>",
"   <p>",
"    Additional factors beyond c-MYC translocation must be present for the development of BL. In support of this idea, a small percentage of HIV positive persons and healthy controls have c-MYC translocations in B lymphocytes isolated from enlarged lymph nodes that do not appear to predict the emergence of later lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     c-MYC in normal cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The c-MYC gene encodes a ubiquitously expressed nuclear phosphoprotein that functions as a pleiotropic transcriptional regulator controlling cell proliferation, differentiation, and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/4\">",
"     4",
"    </a>",
"    ]. In vivo, c-MYC is found mainly in heterodimeric complexes with the related protein MAX; these heterodimers bind to the \"E box consensus sequence\" and directly activate transcription. The MYC-MAX interaction is required for c-MYC to stimulate transcription and cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Remarkably, there appear to be thousands of bona fide",
"    <span class=\"nowrap\">",
"     MYC/MAX",
"    </span>",
"    binding sites in the genome that permit MYC to regulate the expression of thousands of genes, leading to the idea that it may be better viewed as a global regulator of chromatin and gene expression than as a conventional transcription factor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As a result, cells that express high levels of c-MYC produce far more RNA per cell than those that do not [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/12\">",
"     12",
"    </a>",
"    ]. The net effect of this enhanced gene expression is to support both cell cycle progression and Warburg metabolism, which act together to permit cell growth and proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    c-MYC activity is normally regulated by the amount of MAX available to form MYC-MAX heterodimers and by competition from complexes formed by MAX and other proteins. MAX can form homodimers (MAX-MAX) and other heterodimers with MAD family proteins (ie, MNT and MGA) that can act as negative regulators of transcription and block MYC-dependent transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is postulated that MAD-MAX or MNT-MAX heterodimers inhibit c-MYC function, either by sequestering MAX and preventing the formation of",
"    <span class=\"nowrap\">",
"     MYC/MAX",
"    </span>",
"    heterodimers, or by competing with",
"    <span class=\"nowrap\">",
"     MYC/MAX",
"    </span>",
"    heterodimers for binding to the same target sites. Upregulation of MYC leads to a switch favoring MYC-MAX over MNT-MAX complexes at the promoters of target genes, thereby promoting cell cycle progression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/16\">",
"     16",
"    </a>",
"    ]. Overexpression of MNT inhibits MYC-induced cell cycle entry, consistent with a hypothesis of competitive binding to MAX. In non-Hodgkin lymphomas carrying c-MYC translocations, therefore, it is likely that constitutive expression of c-MYC increases the ratio of",
"    <span class=\"nowrap\">",
"     MYC/MAX",
"    </span>",
"    complexes over competitive MAX heterodimers, leading to upregulation of a program of gene expression that promotes growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     c-MYC overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;BL tumors are characterized by an inappropriately high expression of the c-MYC transcription factor through at least one of the following mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal translocations place the DNA coding sequences for c-MYC under the control of immunoglobulin gene enhancers that are constitutively active in mature B cells.",
"     </li>",
"     <li>",
"      5' regulatory regions normally present within the c-MYC DNA sequence are mutated or moved as a direct result of the translocation.",
"     </li>",
"     <li>",
"      Mutations of the c-MYC gene result in amino acid substitutions that stabilize the c-MYC protein and decrease its proteosome-mediated degradation, thereby increasing its half-life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Substantial experimental evidence has shown that constitutive expression of c-MYC influences the growth of B cells in vitro and in vivo, consistent with a role in B cell lymphomagenesis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vitro, the expression of a c-MYC oncogene in Epstein Barr virus (EBV)-immortalized human B cells leads to their malignant transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In vivo, the targeted expression of a c-MYC oncogene in the B cell lineage of transgenic mice leads to the development of B cell malignancy at a relatively high frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gene expression profiling has also confirmed the overexpression of c-MYC target genes, differential expression of normal germinal center genes, and decreased expression of MHC class I and NF-kB target genes in BL [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chromosomal translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In virtually all cases, BL is associated with a translocation between the long arm of chromosome 8, the site of the c-MYC oncogene (8q24), and one of three locations on Ig genes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Ig heavy chain gene on chromosome 14 &mdash; resulting in the t(8;14)(q24;q32) found in 80 percent of BL.",
"     </li>",
"     <li>",
"      The kappa light chain gene on chromosome 2 &mdash; resulting in the t(2;8)(p11;q24) found in 15 percent of BL.",
"     </li>",
"     <li>",
"      The lambda light chain gene on chromosome 22 &mdash; resulting in the t(8;22)(q24;q11) found in 5 percent of BL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The common effect of these translocations is that the translocated c-MYC allele is expressed constitutively in tumor cells, as opposed to the tight regulation of c-MYC levels in normal B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'c-MYC in normal cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although fairly homogeneous at the microscopic level, these translocations display a high degree of molecular heterogeneity. The specific gene breakpoint sites vary not only by translocation but also by clinical context (ie, endemic versus sporadic cases):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The breakpoint sites on chromosome 8 found in t(8;14) are located 5' and centromeric to c-MYC, whereas the sites found in t(2;8) and t(8;22) map 3' to c-MYC [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In endemic (African) cases, the breakpoint on chromosome 14 involves the heavy chain joining region, while in non-endemic cases, the translocation involves the heavy chain class-switch region [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In endemic cases, the breakpoint in chromosome 8 usually lies adjacent to c-MYC, while in sporadic cases it often lies in intron 1 within the gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This molecular heterogeneity precludes the development of sensitive polymerase chain reaction (PCR) based testing for these translocations. Instead, these translocations are identified either by karyotyping of metaphase chromosomes or by fluorescent in situ hybridization (FISH).",
"   </p>",
"   <p>",
"    Work using mouse models has shed light on the possible mechanisms that lead to c-MYC translocations. Translocations involving the class-switch region of the immunoglobulin heavy chain gene and c-MYC occur with surprisingly high frequency in activated B cells undergoing class-switch recombination. These &ldquo;mistakes&rdquo; occur during the recombination event that allows B cells to switch from the expression of IgM to the expression of other immunoglobulin types and require the enzyme activation-induced cytidine deaminase (AID) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/25\">",
"     25",
"    </a>",
"    ]. AID is an essential co-factor for normal class-switch recombination. Other work has shown that c-MYC tends to lie in close proximity to the immunoglobulin heavy chain locus in the nuclei of B cells, which may explain in part why c-MYC is often involved in such translocations. It is hypothesized that most cells bearing these translocations die rapidly, as unbridled c-MYC expression is a potent inducer of apoptosis (programmed cell death) in normal cells. How BL cells escape this fate is largely unknown; in some tumors, however, loss of p53 function may abrogate c-MYC-induced apoptosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Other genetic lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, up to 5 percent of tumors with features that are otherwise typical of BL lack c-MYC rearrangements. Other mechanisms leading to the increased expression of c-MYC include interference with the 5' regulatory regions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stabilization of the protein product.",
"   </p>",
"   <p>",
"    5' regulatory regions normally present within the c-MYC DNA sequence can be mutated or moved as a direct result of the translocation. Liberation of c-MYC from normal regulation can result in increased expression. The c-MYC first",
"    <span class=\"nowrap\">",
"     exon/first",
"    </span>",
"    intron border, where c-MYC regulatory sequences are located, can be either decapitated by the translocations described in the section above or undergo mutation in translocated alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/21,26\">",
"     21,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, the transactivation domain of the c-MYC protein encoded in exon 2 can undergo amino acid substitutions, which interfere with modulation of c-MYC activity by p107 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Other mutations may increase protein stabilization or decrease degradation by the proteasome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557363\">",
"    <span class=\"h2\">",
"     Consequences of c-MYC overexpression",
"    </span>",
"    &nbsp;&mdash;&nbsp;BL may be the fastest growing human cancer, and c-MYC overexpression is believed to be responsible for many of the alterations that support the rapid growth of BL tumors cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/29\">",
"     29",
"    </a>",
"    ]. Included among these MYC-dependent activities are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased glucose utilization and a switch to so-called Warburg metabolism, in which cells mainly rely on glycolysis for ATP production instead of oxidative phosphorylation.",
"     </li>",
"     <li>",
"      Increased glutamine metabolism, which creates metabolic intermediates that are needed for membrane biogenesis.",
"     </li>",
"     <li>",
"      Upregulation of rRNA expression and ribosome biogenesis, leading to increased protein synthesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other genetic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the presence of c-MYC translocations in the vast majority of BL cases, most tumors contain additional chromosomal abnormalities, the molecular implications of which are poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/30\">",
"     30",
"    </a>",
"    ]. Of interest, BL cases appear to have fewer additional genetic lesions than DLBCL or unclassifiable aggressive B cell lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have reported a high frequency of somatic mutations that appear to involve the transcription factor TCF3, its inhibitor ID3, or downstream targets (eg, CCND3):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, high-throughput RNA sequencing and RNA interference screening identified recurrent mutations in components of the p53, cyclin",
"      <span class=\"nowrap\">",
"       D3/CDK6,",
"      </span>",
"      PI(3) kinase, and tonic BCR signalling pathways [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/32\">",
"       32",
"      </a>",
"      ]. Approximately 70 percent of sporadic BL cases had mutations in TCF3 or ID3. Mutations in CCND3 (a gene encoding cyclin D3, a key regulator of cell cycle progression) were present in 38 percent.",
"     </li>",
"     <li>",
"      In another study, complete genome sequencing of BL tumor tissue and germline tissue from the same individual identified mutations of potential interest that were further evaluated with exome sequencing of 59 BL cases and 94 DLBCL cases [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/33\">",
"       33",
"      </a>",
"      ]. Mutations in ID3 were identified in 34 percent of BL. They were not present in DLBCL.",
"     </li>",
"     <li>",
"      In a third study, whole genome and transcriptome sequencing of four BL cases identified seven recurrently mutated genes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/34\">",
"       34",
"      </a>",
"      ]. Further evaluation of these genes in an extension cohort demonstrated ID3 mutations in 36 of 53 (68 percent) of patients with BL but only 6 of 47 (13 percent) of other B cell lymphomas with Ig MYC translocation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TCF3 appears to stimulate survival through the",
"    <span class=\"nowrap\">",
"     BCR/PI3K",
"    </span>",
"    signalling pathway, which upregulates cyclin D3. Normally, TCF3 also induces its own inhibitor (ID3), but this negative feedback loop appears to be broken in BL, as the mutations seen in BL appear to activate TCF3 and inactivate ID3. Further study is needed to confirm and further clarify the role of these other pathways in the pathogenesis of BL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12461909\">",
"    <span class=\"h2\">",
"     Other tumors with c-MYC translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other lymphoid tumors may have c-MYC translocations similar or identical to those found in BL, including diffuse large B cell lymphomas, multiple myeloma, and a subset of unclassifiable B cell lymphomas with some features of BL. In several studies of the latter tumors, cases with &ldquo;Burkitt-like&rdquo; features frequently had dual c-MYC and B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (BCL-2) translocations (ie, \"double hit\" lymphomas) and were associated with an extremely poor clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Another study found that these \"double hit\" lymphomas could be distinguished from BL by their expression of BCL-2, expression of",
"    <span class=\"nowrap\">",
"     IRF4/MUM1,",
"    </span>",
"    Ki-67 less than 95 percent, and absence of Epstein Barr virus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/37\">",
"     37",
"    </a>",
"    ]. Many of these cases may represent &ldquo;transformed&rdquo; follicular lymphomas, in which the c-MYC translocation is acquired as a secondary event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=see_link&amp;anchor=H26243875#H26243875\">",
"     \"Pathobiology of follicular lymphoma\", section on 'Translocations involving BCL-2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic Epstein-Barr virus (EBV) infection appears to play a role in virtually all cases of endemic (African) BL and a minority of sporadic and immunodeficiency-associated BL. However, data suggest that EBV infection alone cannot account for the development of endemic BL and that the etiology is likely polymicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/1,38\">",
"     1,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with some other infections are more likely to have a persistent acute phase of initial EBV infection. This prolonged acute phase with its associated B cell expansion may increase the likelihood of acquisition of translocations involving the c-MYC locus. Proposed organisms associated with persistent EBV infection and BL development include HIV, malaria, and arboviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2791/abstract/1\">",
"     1",
"    </a>",
"    ]. The specific role of these organisms in the pathogenesis of BL remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Epstein Barr virus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal Epstein Barr virus (EBV) infection is present in virtually all cases of endemic BL, approximately 30 percent of sporadic BL, and 40 percent of immunodeficiency-associated BL. The pathobiologic role of EBV infection in the development of BL is poorly understood.",
"   </p>",
"   <p>",
"    One hypothesis is that EBV infection stimulates B cell expansion during which process translocations may occur, leading to the overexpression of c-MYC. Once BL emerges, the EBV infection is thought to have little effect on tumor maintenance. Of interest, EBV infection in BL displays a peculiar latent infection phenotype, characterized by the lack of expression of the EBV transforming proteins LMP-1 and EBNA-2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link&amp;anchor=H10#H10\">",
"     \"Virology of Epstein-Barr virus\", section on 'Transformation and latent proteins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EBV-positive and EBV-negative Burkitt lymphomas may arise from different stages of B cell development. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cell of origin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burkitt lymphoma (BL) encompasses a group of highly aggressive B cell neoplasms with three distinct clinical forms: endemic, sporadic, and immunodeficiency-associated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BL is derived from germinal or post-germinal center B cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cell of origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of BL is dependent upon the constitutive expression of the c-MYC proto-oncogene located at chromosome 8q24, which encodes the c-MYC transcription factor. This transcription factor modulates the expression of target genes that regulate many cellular processes, including cell growth, division, and death. Tumor cells maintain high expression of c-MYC through various mechanisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chromosomal translocations place the DNA coding sequences for c-MYC under the control of immunoglobulin gene enhancers that are constitutively active in mature B cells. The translocations include: t(8;14), t(2;8), and t(8;22). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chromosomal translocations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      5' regulatory regions normally present within the c-MYC DNA sequence are mutated or moved as a direct result of the translocation or other mutations of the c-MYC gene result in an increased half-life of its protein product. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is incomplete information about how and why B cells acquire chromosomal translocations and other genetic changes that result in the increased expression of c-MYC and the resultant development of BL, but the inherent genomic instability of germinal center B cells is likely a contributing factor. Chronic Epstein Barr virus (EBV) infection appears to play a role in virtually all cases of endemic (African) BL and a minority of sporadic and immunodeficiency-associated BL. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/2\">",
"      Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/3\">",
"      Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 2011; 117:3596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/4\">",
"      Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18:3707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/5\">",
"      Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010; 149:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/6\">",
"      M&uuml;ller JR, Janz S, Goedert JJ, et al. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci U S A 1995; 92:6577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/7\">",
"      Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/8\">",
"      Blackwood EM, L&uuml;scher B, Eisenman RN. Myc and Max associate in vivo. Genes Dev 1992; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/9\">",
"      Gu W, Cechova K, Tassi V, Dalla-Favera R. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc Natl Acad Sci U S A 1993; 90:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/10\">",
"      Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/11\">",
"      Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/12\">",
"      Lov&eacute;n J, Orlando DA, Sigova AA, et al. Revisiting global gene expression analysis. Cell 2012; 151:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/13\">",
"      Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/14\">",
"      Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/15\">",
"      Zervos AS, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993; 72:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/16\">",
"      Walker W, Zhou ZQ, Ota S, et al. Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol 2005; 169:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/17\">",
"      Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987; 49:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/18\">",
"      Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/19\">",
"      Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/20\">",
"      Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/21\">",
"      Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982; 79:7824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/22\">",
"      ar-Rushdi A, Nishikura K, Erikson J, et al. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983; 222:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/23\">",
"      Pelicci PG, Knowles DM 2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986; 83:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/24\">",
"      Neri A, Barriga F, Knowles DM, et al. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1988; 85:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/25\">",
"      Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006; 440:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/26\">",
"      Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987; 238:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/27\">",
"      Bhatia K, Huppi K, Spangler G, et al. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/28\">",
"      Gu W, Bhatia K, Magrath IT, et al. Binding and suppression of the Myc transcriptional activation domain by p107. Science 1994; 264:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/29\">",
"      Dang CV. MYC on the path to cancer. Cell 2012; 149:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/30\">",
"      Toujani S, Dessen P, Ithzar N, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One 2009; 4:e7089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/31\">",
"      Seegmiller AC, Garcia R, Huang R, et al. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol 2010; 23:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/32\">",
"      Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/33\">",
"      Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/34\">",
"      Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/35\">",
"      Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999; 17:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/36\">",
"      Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/37\">",
"      Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2791/abstract/38\">",
"      Chene A, Donati D, Orem J, et al. Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol 2009; 19:411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4723 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2791=[""].join("\n");
var outline_f2_46_2791=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      c-MYC in normal cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      c-MYC overexpression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chromosomal translocations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1557363\">",
"      Consequences of c-MYC overexpression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other genetic lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12461909\">",
"      Other tumors with c-MYC translocations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Epstein Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24215?source=related_link\">",
"      Pathobiology of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_46_2792="Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma";
var content_f2_46_2792=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2792/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/46/2792/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with favorable prognosis stage I-II Hodgkin lymphoma (formerly called Hodgkin's disease) are increasingly being treated with modified radiation therapy in combination with chemotherapy. These newer treatment programs are based, in part, upon the presence or absence of unfavorable prognostic factors.",
"   </p>",
"   <p>",
"    Favorable and unfavorable risk factors are discussed in more detail separately. Briefly, factors associated with an unfavorable outcome include: large mediastinal adenopathy, erythrocyte sedimentation rate (ESR) of 50",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    or greater, and systemic B symptoms (ie, fever, night sweats, weight loss), and four or more regions of involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"     \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing concern for the long-term consequences of therapy (eg, cardiac disease, second malignancies) has prompted a reevaluation and modification of the aggressive approaches developed for the staging and treatment of early stage Hodgkin lymphoma in the 1970s and 1980s that included the use of large field irradiation alone.",
"   </p>",
"   <p>",
"    Among the issues that have been addressed are the radiation dose and radiation field size, whether given alone or with chemotherapy, the optimal chemotherapy regimen, the optimal number of chemotherapy cycles, and the efficacy of combination chemotherapy alone. These studies will be discussed here. Most have relatively short follow-up or are ongoing and would not be expected to demonstrate survival differences. High relapse rates and significant acute toxicity are the main criteria for an adverse outcome.",
"   </p>",
"   <p>",
"    Current recommendations for treatment of favorable prognosis Hodgkin lymphoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY PLUS RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials employing a combination of radiation therapy plus chemotherapy have focused on maintaining a low risk of relapse while minimizing late complications of treatment through systematic reduction of both modalities. The success of these trials depends in part on the careful selection of patients with favorable prognostic features. Although there is a tendency to publish interim analyses of ongoing trials, one must be careful not to apply these data too early into routine clinical practice, as the follow-up times are short and, with reduction in treatment, the time to recurrence may be delayed beyond that seen with more aggressive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Optimal chemotherapy combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of combined modality therapy are based upon the premise that this approach results in a very high freedom from recurrence in early stage Hodgkin lymphoma, and that the efficacy of combining chemotherapy with radiation can be maintained by using chemotherapy regimens that contain less toxic drug combinations than MOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) or similar alkylating agent-based regimens (C-MOPP, COPP, ChlVPP) and are given for two to four cycles. These regimens are combined with involved field or regional radiation therapy with the assumption that the drugs being tested will be able to control occult abdominal disease in sites not recognized by radiographic staging.",
"   </p>",
"   <p>",
"    Randomized trials had compared this approach to radiation therapy alone using larger (standard) radiation fields (eg, subtotal or total nodal plus splenic irradiation) in patients with favorable prognosis CS I-II Hodgkin lymphoma. More recent trials have limited radiation fields to the initially involved region and have tested the radiation dose and the amount of chemotherapy delivered. The use of chemotherapy alone is also being tested. Results of these studies are summarized in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Common chemotherapy regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     ABVD",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) was designed to have similar or better efficacy and less toxicity than MOPP (",
"    <a class=\"graphic graphic_table graphicRef68131 \" href=\"UTD.htm?0/59/958\">",
"     table 1",
"    </a>",
"    ). In the EORTC H6U trial, 316 patients with unfavorable prognosis, early stage Hodgkin lymphoma who did not undergo laparotomy were randomly assigned to receive mantle irradiation and either ABVD or MOPP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/1\">",
"     1",
"    </a>",
"    ]. At 10 years, ABVD was associated with a significantly higher freedom from progression (90 versus 68 percent), and better hematologic and gonadal tolerance, but increased pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     EBVP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EORTC H7F trial compared six cycles of EBVP followed by involved field irradiation versus subtotal nodal irradiation alone in 333 patients with favorable prognosis CS IA-IIA Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/2\">",
"     2",
"    </a>",
"    ]. The EBVP II regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , one dose per cycle), was proposed as a potentially less toxic regimen than ABVD (two doses per cycle). At six years, the event-free survival rate was significantly higher in the combined chemotherapy and radiation therapy arm (90 versus 81 percent), while the survival rate was identical in both treatment arms (98 versus 96 percent).",
"   </p>",
"   <p>",
"    In contrast, in the H7U trial for patients with unfavorable stage I-II disease, EBVP and involved field radiation therapy was inferior to",
"    <span class=\"nowrap\">",
"     MOPP/ABV",
"    </span>",
"    and involved field radiation therapy for both relapse-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/3\">",
"     3",
"    </a>",
"    ]. This observation suggests that the use of prognostic factors is crucial in selecting patients for treatment with modified chemotherapy and radiation therapy regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Stanford V",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Stanford V regimen has been modified for favorable prognosis patients from the original 12 weeks to 8 weeks, with involved field irradiation to sites of initial involvement (identified radiographically as nodal enlargement of 5.0 cm or greater). The chemotherapy regimen includes weekly administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on weeks 1 and 5),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on weeks 1, 3, 5, and 7),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on weeks 1, 3, 5, and 7),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 36, then taper off),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    (1.4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on weeks 2, 4, 6, and 8),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on weeks 2, 4, 6, and 8), and VP-16 (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 15 and 16, and days 43 and 44).",
"   </p>",
"   <p>",
"    This regimen uses brief but intense chemotherapy to control Hodgkin lymphoma outside of initially involved sites in favorable prognosis CS I-II patients. An essential part of this regimen is the use of radiation therapy to sites of initial bulky disease (ie, &gt;5 cm). In a series of 87 patients with early stage Hodgkin lymphoma and a median follow-up of 10.6 years, the estimated rates of freedom from progression, disease-specific survival, and overall survival at 10 years were 94, 99, and 94 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Short course chemotherapy plus large field irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of the trials in this section is to evaluate the efficacy of short courses of chemotherapy when added to what was standard treatment (ie, extended field irradiation alone) when the trials were originally devised.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The German Hodgkin's Study Group (GHSG) HD7 trial (1994 to 1998) accrued 643 favorable prognosis patients with CS IA-IIB Hodgkin lymphoma. The patients were randomly assigned to receive subtotal nodal and splenic irradiation with or without two courses of ABVD. There was a significantly improved seven-year freedom from treatment failure in the radiation therapy and chemotherapy arm (88 percent) versus radiation therapy alone (67 percent). No survival differences were seen [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a phase III SWOG study, 348 patients with favorable prognosis CS IA-IIA supradiaphragmatic disease without laparotomy were randomly assigned to receive either subtotal lymphoid irradiation (STLI: sequential mantle and",
"      <span class=\"nowrap\">",
"       periaortic/splenic",
"      </span>",
"      fields) alone or combined modality treatment (CMT) with three courses of AV (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ) followed by STLI [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This study was terminated early because of a superior three-year failure-free survival for patients on the CMT arm (94 percent) compared with the STLI arm (81 percent, p&lt;0.001). Toxicity was minimal, with one treatment-related death in each arm. At the time of the report, there were no differences in overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These trials use large field irradiation, which is no longer the standard in the treatment of stage I-II Hodgkin lymphoma so their relevance to current practice is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Modified chemotherapy and involved field irradiation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EORTC H8F trial (1993 to 1998) randomly assigned 542 patients with favorable prognosis CS IA-IIA Hodgkin lymphoma to either three cycles of",
"      <span class=\"nowrap\">",
"       MOPP/ABV",
"      </span>",
"      hybrid plus involved field irradiation or subtotal nodal radiotherapy (mantle and paraaortic-splenic irradiation) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/7\">",
"       7",
"      </a>",
"      ]. The combination therapy arm had significantly superior five-year relapse-free survival (99 versus 78 percent), and superior 10-year overall survival (97 versus 92 percent). Both arms had similar response rates and cumulative risk for second cancers. This trial concluded that three cycles of standard chemotherapy and involved field irradiation is sufficient treatment for favorable prognosis stage I-II Hodgkin lymphoma. Survival differences were seen at 10 years that were not seen at 5 years suggesting that an inferior FFTF might result in a lower overall survival, especially when there is sufficient follow-up time.",
"     </li>",
"     <li>",
"      The German Hodgkin Study Group HD10 Trial (1998 to 2003) randomly assigned 1370 patients to receive one of the following four treatments: two cycles of ABVD followed by 30 Gy involved field radiation therapy; two cycles of ABVD followed by 20 Gy involved field radiation therapy; four cycles of ABVD followed by 30 Gy involved field radiation therapy; or four cycles of ABVD followed by 20 Gy involved field radiation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/8\">",
"       8",
"      </a>",
"      ]. At median follow-up of 7.5 years, there was no significant difference between four and two cycles of ABVD chemotherapy in five-year overall survival (97.1 versus 96.6 percent), freedom from treatment failure (93.0 versus 91.1 percent), and progression-free survival (93.5 versus 91.2 percent). Estimated eight-year survival rates were also similar (95 versus 94 percent). Similarly, there was no significant difference between 30 and 20 Gy involved field radiation therapy in five-year overall survival (OS, 97.7 versus 97.5 percent), freedom from treatment failure (FFTF, 93.4 versus 92.9 percent), and progression-free survival (PFS, 93.7 versus 93.2 percent). There was also no significant difference in terms of OS, FFTF, and PFS when all four arms were compared.",
"      <br/>",
"      <br/>",
"      However, there were significant differences in major toxicity (WHO grade",
"      <span class=\"nowrap\">",
"       III/IV)",
"      </span>",
"      between four and two cycles of ABVD in the overall number of events (52 versus 33 percent) including leukopenia (24 versus 15 percent) and hair loss (28 versus 15 percent); and between 30 and 20 Gy involved field radiation therapy (all events, 8.7 versus 2.9 percent), dysphagia (3 versus 2 percent), and mucositis (3.4 versus 0.7 percent).",
"      <br/>",
"      <br/>",
"      The results of this trial suggest that two cycles of ABVD followed by 20 Gy involved field radiation therapy may be sufficient treatment for patients with favorable presentations of stage I-II Hodgkin lymphoma. It is important to note that specific eligibility criteria for this trial included patients with no more than two sites of disease, no extranodal extension, and ESR less than 50 (less than 30 if B symptoms present).",
"     </li>",
"     <li>",
"      The GHSG 13 trial is a four-arm study comparing two cycles of either ABVD, AVD, ABV, or AV, each followed by 30 Gy of involved-field irradiation in CS I-II patients without risk factors. This trial is designed to determine the most important drugs in the ABVD regimen, focusing especially on the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      components.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiation volume and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time there has been a movement to decrease the field of radiation in order to limit acute and long-term toxicities while maintaining survival rates. Various definitions have been applied. For our discussion, the following definitions will be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended-field radiation &mdash; Radiation field includes not only the clinically involved nodes, but also the adjacent, clinically uninvolved sites (eg, mantle field or inverted-Y field).",
"     </li>",
"     <li>",
"      Involved-field radiation &mdash; Radiation field encompasses all of the clinically involved regions (eg, mediastinal plus low bilateral supraclavicular field which covers the entire mediastinum) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Involved-node radiation &mdash; Radiation field includes pre- and post-chemotherapy nodal volumes plus a margin of healthy tissue &le;5 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Completed trials evaluating radiation volume when combined with chemotherapy in poor prognosis CS I-II patients suggest that involved field irradiation is sufficient radiation when combined with four cycles of ABVD. The 10-year FFTF in 133 patients in the Milan trial of ABVD plus involved or extended field radiation was 93 and 96 percent, respectively, and no differences were seen among 995 patents enrolled in the EORTC H8U trial (unfavorable prognosis stage I-II patients) comparing involved field verses more extensive field irradiation.",
"   </p>",
"   <p>",
"    Two ongoing trials in favorable prognosis early stage Hodgkin lymphoma are evaluating radiation dose to involved sites after chemotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The GHSG HD10 trial began in 1998 and is discussed above.",
"     </li>",
"     <li>",
"      The EORTC H9F trial is evaluating 36 Gy, 20 Gy, or no radiation to involved sites in patients who have achieved a complete remission after six cycles of EBVP II. The no radiation arm has been closed early because of a greater than expected number of recurrences in this arm. Although current follow-up is short, no differences have been seen between the 36 and 20 Gy radiation therapy arms at a median follow-up time of 33 months [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY ALONE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chemotherapy alone versus radiation alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probably the first published experience of the use of MOPP chemotherapy alone in early stage Hodgkin lymphoma comes from Uganda, where no radiation therapy was available [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/13\">",
"     13",
"    </a>",
"    ]. Based upon this and other limited experience, two randomized trials were devised to compare radiation therapy alone to MOPP alone in laparotomy staged patients. Both studies are now dated because of the use of MOPP and the requirement for staging laparotomy.",
"   </p>",
"   <p>",
"    A National Cancer Institute study was initially designed to include patients with intermediate prognosis Hodgkin lymphoma without large mediastinal adenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/14\">",
"     14",
"    </a>",
"    ]. Although the trial included patients with favorable prognosis PS IIA Hodgkin lymphoma, the most favorable patients with PS IA disease in peripheral sites were treated with radiation therapy alone and patients with an unfavorable prognosis (B symptoms, large mediastinal adenopathy, and limited stage III disease) were included. The patients were randomized to six months of MOPP chemotherapy alone or subtotal nodal irradiation alone. No difference in disease-free or overall survival was seen at 10 years.",
"   </p>",
"   <p>",
"    A second study, The National Cancer Institute of Canada (NCIC) and Eastern Cooperative Oncology Group CTG HD6 Study is a modification of the NCI and Italian studies with the randomization of clinically staged patients and the use of ABVD as the chemotherapy regimen. The study excluded patients with a &lt;3 cm stage IA lymphocyte predominant or nodular sclerosis HL involving the high neck or epitrochlear region who had an erythrocyte sedimentation rate (ESR) &lt;50",
"    <span class=\"nowrap\">",
"     mm/hr.",
"    </span>",
"    Patients with non-bulky CS I-II disease were stratified into favorable risk (age &lt;40, ESR &lt;50, and &lt;3 sites of disease) and unfavorable risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/15\">",
"     15",
"    </a>",
"    ]. Favorable risk patients were randomly assigned to treatment with either extended-field irradiation or four to six cycles of ABVD, and unfavorable risk patients were randomly assigned to receive either two cycles of ABVD followed by radiation therapy or four to six cycles of ABVD.",
"   </p>",
"   <p>",
"    At a median follow-up of 11.3 years, chemotherapy alone was associated with a lower rate of freedom from disease progression (FFDP, 87 versus 92 percent) but a higher rate of overall survival (OS, 94 versus 87 percent) at 12 years in the entire population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/16\">",
"     16",
"    </a>",
"    ]. This improvement in survival was attributed to an increased rate of non-relapse mortality among patients treated with sub-total nodal RT. On a subset analysis of patients with a favorable prognosis, there was no significant difference in FFDP (98 percent in both groups) or OS (89 versus 87 percent). A criticism of this trial is the long time to completion of patient accrual such that the \"standard arm\", originally defined as extended-field irradiation, is currently no longer viewed as standard treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chemotherapy alone versus chemotherapy plus radiation therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Children's Cancer Group (CCG) randomly assigned 501 patients who obtained a complete response to chemotherapy to receive involved field radiation or no further treatment. All stages were included. The chemotherapy alone arm in this trial has been stopped; interim analysis showed significantly increased recurrences in the no radiation arm that met the stopping rules [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/17\">",
"       17",
"      </a>",
"      ]. At three years, based on treatment received, event-free survival was 93 percent with involved field radiation and 85 percent without radiation.",
"     </li>",
"     <li>",
"      The Memorial Sloan-Kettering Cancer Center trial randomly assigned CS I-IIIA patients who achieved a complete remission after six cycles of ABVD to receive either mantle irradiation (35 Gy) or no further treatment. Patients with large mediastinal adenopathy and nodes &gt;10 cm were not eligible. However, CS IIB and CS IIIA patients were included. Thus, this trial was not restricted to early stage favorable prognosis Hodgkin lymphoma. After only 152 patients were accrued over a 10-year period, the trial was closed due to slow accrual. No significant differences for the combined modality versus chemotherapy alone arm were seen in freedom from progression (86 versus 81 percent, respectively) and overall survival (97 versus 90 percent, respectively) at a median follow-up of 60 months. The trial, however, was underpowered to determine if the two treatment approaches are truly equivalent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA) randomly assigned 277 patients with CS I-II Hodgkin lymphoma to receive either six monthly cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CVPP) followed by involved-field radiation therapy to 30 Gy, or to receive six cycles of modified CVPP alone (omission of cyclophosphamide on day eight) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/19\">",
"       19",
"      </a>",
"      ]. At 84 months, disease-free survival (DFS) for the combined modality therapy arm was significantly longer than that of the chemotherapy alone arm (71 versus 62 percent). On subgroup analysis, the differences between the two arms were highly significant among patients with unfavorable features (age &gt;45, &gt;2 involved sites, or bulky disease), with DFS of 75 percent in the combined modality therapy arm versus 34 percent in the chemotherapy alone arm.",
"     </li>",
"     <li>",
"      In a randomized trial from Tata Memorial Hospital, complete responders following six cycles of ABVD were randomly assigned to receive either involved-field radiation therapy or no further treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients of all stages were included; 55 percent had CS I-II disease. Significant differences in six-year event-free survival (88 versus 76 percent) and overall survival (100 versus 89 percent) were observed, favoring the combined modality therapy arm. The trial contained a high proportion of pediatric patients. Seventy-one percent of cases were of mixed cellularity histology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nearly all of the chemotherapy alone trials have been conducted in favorable prognosis patients. These trials have had a number of problems with design, patient accrual, as well as variations in the type of chemotherapy and field size of radiation therapy utilized. Despite this, most of the trials have demonstrated significantly higher recurrence rates in the chemotherapy alone arms versus the chemotherapy plus radiation therapy arms.",
"   </p>",
"   <p>",
"    Given the relatively short follow-up and the relatively small numbers of patients entered in many of the trials, significant survival differences have not been seen in most of the trials. However, a Cochrane Review of all the randomized trials in early stage Hodgkin lymphoma of chemotherapy versus combined chemotherapy and radiation therapy (1583 patients) reveals a significant survival advantage for patients who receive both chemotherapy and radiation therapy (HR 0.40; 95% CI 0.27-0.59) compared with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most trials, the freedom from treatment failure with mantle irradiation alone in clinically staged patients is inferior to results with more extensive radiation therapy or combined radiation therapy plus chemotherapy. In contrast, following a negative laparotomy, early stage patients have a very good outcome after mantle irradiation alone. However, in an era when staging laparotomy is rarely performed, nearly all patients with favorable prognosis early stage classical Hodgkin lymphoma should be treated with modified combined radiation therapy and chemotherapy as guided by current clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mantle irradiation alone in PS IA-IIA patients &mdash; To determine the role of prophylactic abdominal irradiation in early stage Hodgkin lymphoma, the EORTC H-5 trial (1977 to 1982) compared the use of mantle and paraaortic&ndash;splenic pedicle irradiation to mantle irradiation alone in laparotomy-negative patients with favorable early stage Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. This study included only patients with nodular sclerosis or lymphocyte predominant histology, age &le;40 years, PS I or PS II with mediastinal adenopathy, and an ESR &lt;70",
"      <span class=\"nowrap\">",
"       mm/hour.",
"      </span>",
"      After 15 years of follow-up, no differences were seen between the two treatment arms, either for cumulative treatment failure probability or overall survival.",
"     </li>",
"     <li>",
"      In the single-arm Harvard University Medical School trial for laparotomy-staged IA-IIA Hodgkin lymphoma patients, the freedom from treatment failure at five years was 89 percent for stage IA and 80 percent for stage IIA disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/25\">",
"       25",
"      </a>",
"      ]. The 10-year survival was 98 percent.",
"     </li>",
"     <li>",
"      Mantle irradiation alone in CS IA-IIA patients &mdash; Results from prospective and retrospective studies of mantle irradiation alone for unselected CS I-II patients have been disappointing, with relapse rates approaching 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/26\">",
"       26",
"      </a>",
"      ]. These high recurrence rates in unselected patients are not surprising, as more than 20 percent of CS I-II patients have occult abdominal involvement; absence of treatment (eg, radiation therapy or chemotherapy) to cover potential abdominal disease therefore results in higher recurrence rates than achieved with more extensive treatment. When mantle irradiation was restricted to clinically staged, asymptomatic patients with a single lymph node region involved (CS IA), better results have been seen with 10- to 15-year freedom-from-recurrence rates of 58 to 81 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mantle irradiation alone in patients with low risk of abdominal involvement &mdash; The EORTC defined a subgroup of CS I-II patients (women &lt;40 years of age with CS IA nodular sclerosis Hodgkin lymphoma or nodular lymphocyte predominant Hodgkin lymphoma and an ESR &lt;50",
"      <span class=\"nowrap\">",
"       mm/hour)",
"      </span>",
"      that were treated with mantle irradiation alone without staging laparotomy in the EORTC H7-VF (VF, very favorable) and H8-VF trials. This was a group of patients that would have been expected to have a low risk of abdominal involvement by prognostic factors. In the H7VF trial, 40 patients were treated according to this concept and complete remission was reached in 95 percent. However, 23 percent relapsed, yielding a six-year event-free survival rate of 66 percent, a relapse-free survival rate of 73 percent, and overall and cause-specific survival rates of 96 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2792/abstract/29\">",
"       29",
"      </a>",
"      ]. These relapse rates were thought to be unacceptably high in this selected subgroup of stage IA patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11003278\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with early (stage I-II) Hodgkin lymphoma (HL), there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Patients with favorable prognosis stage I-II HL are increasingly being treated with modified radiation therapy in combination with chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"       \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trials employing a combination of radiation therapy plus chemotherapy have focused on maintaining a low risk of relapse while minimizing late complications of treatment through systematic reduction of both modalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chemotherapy plus radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nearly all of the trials investigating chemotherapy alone have been conducted in favorable prognosis patients. These trials have had a number of problems with design, patient accrual, as well as variations in the type of chemotherapy and field size of radiation therapy utilized. Despite this, most of the trials have demonstrated significantly higher recurrence rates in the chemotherapy alone arms versus the chemotherapy plus radiation therapy arms. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Chemotherapy alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most trials, the freedom from treatment failure with mantle irradiation alone in clinically staged patients is inferior to results with more extensive radiation therapy or combined radiation therapy plus chemotherapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Radiation therapy alone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/1\">",
"      Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/2\">",
"      Carde P, Noordijk E, Hagenbeek A, et al. Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease: The EORTC-GPMC H7F randomized trial (abstract). Proc Am Soc Clin Oncol 1997; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/3\">",
"      Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24:3128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/4\">",
"      Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 2013; 24:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/5\">",
"      Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/6\">",
"      Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19:4238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/7\">",
"      Ferm&eacute; C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/8\">",
"      Engert A, Pl&uuml;tschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/9\">",
"      Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/10\">",
"      Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008; 26:5170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/11\">",
"      Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/12\">",
"      Thomas J, Ferme C, Noordijk E, et al. Six cycles of EBVP followed by 36Gy involved-field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stage I-II Hodgkin's Lymphoma: the EORTC-GELA strategy in 771 patients. Eur J Haematol 2004; 73:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/13\">",
"      Olweny CL, Katongole-Mbidde E, Kiire C, et al. Childhood Hodgkin's disease in Uganda: a ten year experience. Cancer 1978; 42:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/14\">",
"      Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 1991; 9:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/15\">",
"      Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/16\">",
"      Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012; 366:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/17\">",
"      Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/18\">",
"      Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104:3483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/19\">",
"      Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/20\">",
"      Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004; 22:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/21\">",
"      Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2010; 95:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/22\">",
"      Herbst C, Rehan FA, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; :CD007110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/23\">",
"      Tubiana M, Henry-Amar M, Hayat M, et al. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/24\">",
"      Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988; 6:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/25\">",
"      Ng AK, Li S, Neuberg D, et al. Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease. Ann Oncol 2006; 17:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/26\">",
"      Sutcliffe SB, Gospodarowicz MK, Bush RS, et al. Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 1985; 4:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/27\">",
"      Ganesan TS, Wrigley PF, Murray PA, et al. Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. Br J Cancer 1990; 62:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/28\">",
"      Wirth A, Byram D, Chao M, et al. Long-term results of mantle irradiation alone in 261 patients with clinical stage I-II supradiaphragmatic Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997; :39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2792/abstract/29\">",
"      Noordijk E, Carde P, Hagenbeek A, et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF,' 'H7-F' and 'H7-U' (abstract). Int J Radiat Oncol Biol Phys 1997; 39:173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4756 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2792=[""].join("\n");
var outline_f2_46_2792=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11003278\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMOTHERAPY PLUS RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Optimal chemotherapy combination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Common chemotherapy regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - ABVD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - EBVP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Stanford V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Short course chemotherapy plus large field irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Modified chemotherapy and involved field irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiation volume and dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CHEMOTHERAPY ALONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chemotherapy alone versus radiation alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chemotherapy alone versus chemotherapy plus radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RADIATION THERAPY ALONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11003278\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4756|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/59/958\" title=\"table 1\">",
"      ABVD chemotherapy for Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=related_link\">",
"      Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_46_2793="Treatment of large granular lymphocyte leukemia";
var content_f2_46_2793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of large granular lymphocyte leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Thierry Lamy, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Thomas P Loughran, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2793/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/46/2793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large granular lymphocyte (LGL) leukemia is characterized by peripheral blood and marrow lymphocytic infiltration with clonal LGLs, splenomegaly, and cytopenias, most commonly neutropenia.",
"   </p>",
"   <p>",
"    The LGL is a morphologically distinct lymphoid subset that is larger than most circulating lymphocytes, and has characteristic azurophilic granules containing acid hydrolases (",
"    <a class=\"graphic graphic_picture graphicRef69027 \" href=\"UTD.htm?0/1/28\">",
"     picture 1",
"    </a>",
"    ). LGLs comprise 10 to 15 percent of normal peripheral blood mononuclear cells. The absolute number of LGLs in the peripheral blood of normal subjects is 200 to",
"    <span class=\"nowrap\">",
"     400/microL.",
"    </span>",
"   </p>",
"   <p>",
"    LGLs arise from two major lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD3 positive T-cell lineage &mdash; Approximately 85 percent of circulating LGLs are CD3 positive, CD57 positive, CD56 negative T cells, representing in vivo antigen-activated effector-memory cytotoxic T cells.",
"     </li>",
"     <li>",
"      CD3 negative NK-cell lineage &mdash; The remaining 15 percent of circulating LGLs are CD3-, CD56+ natural killer (NK) cells. It had been postulated that such NK cells mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. It is now established that NK cells possess specific receptors for MHC class I molecules named \"killer-cell Ig-like inhibitory receptor\" (KIR) and \"killer-cell activating receptor\" (KAR). Interactions between these receptors and MHC class I molecules on target cells may inhibit or activate NK-cell&ndash;mediated cytotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    LGL leukemia can arise from the clonal proliferation of LGLs of T-cell or NK-cell lineage. The management of LGL leukemia will be discussed here. The etiology, clinical features, and diagnosis of T-cell LGL leukemia and the diagnosis and management of NK-cell LGL leukemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=see_link\">",
"     \"Natural killer (NK) cell large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147328340\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with LGL leukemia require treatment at the time of diagnosis. Active treatment is typically reserved for patients with symptomatic disease. This is principally because most cases have an indolent clinical behavior with a median survival over 10 years, and because LGL leukemia cannot be cured by current treatment options. Spontaneous remission of LGL leukemia has been documented very rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3\">",
"     3",
"    </a>",
"    ]. The main goal of treatment for patients with LGL leukemia is the relief of symptoms. Although intuitively sensible, it remains unclear whether achievement of hematologic improvement prolongs survival.",
"   </p>",
"   <p>",
"    Among newly diagnosed patients with asymptomatic LGL leukemia, we suggest observation rather than immediate treatment. Treatment is indicated for relief of symptoms or life-threatening peripheral blood cytopenias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe neutropenia (absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;500/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Moderate neutropenia (absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;1000/microL)",
"      </span>",
"      with recurrent infections",
"     </li>",
"     <li>",
"      Symptomatic or transfusion dependent anemia",
"     </li>",
"     <li>",
"      Severe thrombocytopenia",
"      <span class=\"nowrap\">",
"       (&lt;50,000/microL),",
"      </span>",
"      which is a very rare event",
"     </li>",
"     <li>",
"      Associated autoimmune conditions (eg, rheumatoid arthritis) requiring therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with severe neutropenia as their only symptom may be reluctant to start treatment with immunosuppressive agents. Most experts in the field would suggest initiating immunosuppressive therapy in such patients. A less attractive alternative is the intermittent use of antibiotics and granulocyte colony stimulating factor (G-CSF) during febrile episodes. G-CSF can result in a transient partial correction of the neutropenia in such settings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147328348\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ASYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, immediate treatment is indicated for patients with symptomatic disease. Otherwise, a period of observation is suggested. During the observation period, we perform a complete blood count with differential every 6 to 12 months, along with a clinical examination. Patients are encouraged to contact their health care providers sooner if they have symptoms worrisome of disease progression (eg, recurrent infections, fatigue, dyspnea, bleeding).",
"   </p>",
"   <p>",
"    Approximately 70 percent of patients ultimately require therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3\">",
"     3",
"    </a>",
"    ], most commonly because of recurrent infection secondary to severe neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147328356\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the initiation of active therapy for patients with symptomatic disease, patients with LGL leukemia should undergo a pretreatment evaluation to determine the extent of disease, patient performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"     table 1A-B",
"    </a>",
"    ), and assessment of comorbidities that are likely to have an impact on treatment options.",
"   </p>",
"   <p>",
"    In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with LGL leukemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspirate and biopsy is recommended if the diagnosis is uncertain. This sample should be sent for pathology review, immunophenotyping, cytochemistry, and conventional cytogenetics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no agreed upon standard treatment regimen for symptomatic LGL leukemia. Although experts in the field prefer different specific regimens, there is general agreement that immunosuppressive therapy (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) is the cornerstone of initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The various immunosuppressive treatments have not been directly compared with one another in a prospective fashion, and data come primarily from small, retrospective case series. These series have used different response criteria and provide little information regarding time to response, response and treatment duration, and time to treatment failure.",
"   </p>",
"   <p>",
"    The most promising results have been reported following the use of low-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , either as single agents or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. Prednisone may quicken the initial response when administered as adjunctive therapy with another first-line immunosuppressive agent. However, single agent therapy with prednisone is not recommended because it has a low response rate and does not reduce LGL clones [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A choice among immunosuppressive treatments is primarily made based upon the clinical setting and physician experience [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia &mdash; We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for patients with neutropenia as their primary symptom. For patients with an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;200/microL,",
"      </span>",
"      oral prednisone (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) is administered in addition to the methotrexate for the first month and tapered off by the end of the second month.",
"     </li>",
"     <li>",
"      Autoimmune disorders &mdash; We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for patients with an associated autoimmune disorder (eg, rheumatoid arthritis). In this setting, the use of prednisone is dictated by the accompanying autoimmune disorder. As an example, prednisone may help control joint pain related to rheumatoid arthritis.",
"     </li>",
"     <li>",
"      Anemia &mdash; We prefer either oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (100 mg daily) for patients with anemia. While both of these agents have demonstrated activity in this setting, some clinicians prefer cyclophosphamide for patients with anemia at least partially due to its demonstrated activity in patients with pure red cell aplasia, and its activity in patients with LGL leukemia who progress despite treatment with methotrexate. Other clinicians prefer methotrexate because it can be continued indefinitely as long as it is tolerated, whereas treatment with oral cyclophosphamide is limited to no more than 6 to 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Response rates with the regimens are described in the following sections. The initial immunosuppressive regimen is continued until disease progression or until the maximum length of treatment is reached. (See",
"    <a class=\"local\" href=\"#H1147328393\">",
"     'Response evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weekly low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is the preferred initial therapy for most patients with LGL leukemia, especially for patients with neutropenia as their primary symptom and for patients with an associated autoimmune disorder. Responses are seen in approximately half of patients, with a time to response ranging from 2 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"     5",
"    </a>",
"    ]. The median duration of response ranges from two to four years.",
"   </p>",
"   <p>",
"    Support for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in this setting is primarily derived from small case series and a single prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3,9-14\">",
"     3,9-14",
"    </a>",
"    ]. A phase II Eastern Cooperative Oncology Group (ECOG) study of weekly oral methotrexate plus daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , replaced by daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and prednisone for those not responding after four months of treatment, has finished accrual [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest case series of patients with LGL leukemia, which included 201 patients with T-LGL leukemia, reported an overall response rate of 55 percent (21 percent complete) in 62 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study evaluated the efficacy of oral low-dose pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in 10 patients with T-LGL leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/11\">",
"       11",
"      </a>",
"      ]. Methotrexate was started at a dose of 5.0 to 7.5 mg PO, given once per week in split AM and PM doses, and gradually increased to 15 to 20",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week) over one to three months. In patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      prior to starting methotrexate (in doses of 20 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO), the addition of methotrexate allowed reduction of the daily dose of prednisone to as low as zero to 10",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      without losing its effectiveness on reversal of neutropenia. The complete remission rate was 50 percent; a molecular remission was observed in three of the five patients achieving complete remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is generally well tolerated and can be continued long-term. Common toxicities associated with MTX include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastrointestinal problems such as nausea, stomach upset, and loose stools",
"     </li>",
"     <li>",
"      Stomatitis or soreness of the mouth",
"     </li>",
"     <li>",
"      Macular punctate rash that usually occurs on the extremities and spares the trunk",
"     </li>",
"     <li>",
"      Central nervous system problems including headache, fatigue, or impaired ability to concentrate",
"     </li>",
"     <li>",
"      Alopecia",
"     </li>",
"     <li>",
"      Fever, but infection should be excluded",
"     </li>",
"     <li>",
"      Hematologic abnormalities, particularly macrocytosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One or more of these side effects are seen in some form, at some time, in most patients. Less common, but potentially serious, side effects include hepatotoxicity, pulmonary toxicity, myelosuppression, and nephrotoxicity. Prior to initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, patients should be screened for hepatitis B and hepatitis C virus infections and should undergo a baseline chest radiograph. Hepatic function and complete blood counts should be monitored every four to eight weeks while on therapy. In addition, patients receiving low-dose oral methotrexate should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35829049\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (50 to 100 mg daily) has demonstrated an overall response rate of 55 to 65 percent in patients with previously untreated LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3,9,14,16,17\">",
"     3,9,14,16,17",
"    </a>",
"    ]. This agent, along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , may be particularly effective in patients with LGL leukemia and pure red cell aplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3,16,18,19\">",
"     3,16,18,19",
"    </a>",
"    ]. In addition, responses have been reported in a majority of patients who have failed treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/10\">",
"     10",
"    </a>",
"    ]. The time to response ranges from one to four months. The median duration of response is unknown, but cyclophosphamide should not be administered for longer than 6 to 12 months for responders because the risk of toxicity is related to the cumulative dose of medication.",
"   </p>",
"   <p>",
"    Major toxicities associated with long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy include bone marrow suppression with accompanying cytopenias, increased risk of infection, infertility, and an increased risk of developing secondary malignancies. Cyclophosphamide is teratogenic and contraindicated in pregnant women. Both cystitis and bladder cancer are associated with cyclophosphamide therapy. To minimize bladder toxicity, patients should be advised to take cyclophosphamide in the morning and to drink at least eight glasses (240 mL each) of water daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    A, administered at varying doses, has demonstrated an overall response rate of 56 percent with response rates ranging in different case series from 21 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"     5",
"    </a>",
"    ]. Responses are seen despite survival of the leukemic LGL clone, and relapses on therapy are not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Responses have been reported in patients with pure red cell aplasia and in patients with resistant disease. One series reported higher response rates among patients with an HLADR4 phenotype (present in 32 percent of LGL leukemia and 90 percent of LGL leukemia associated with rheumatoid arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are examples of case series reporting on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for the treatment of LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/9,10,13,14,17,18,21-25\">",
"     9,10,13,14,17,18,21-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series of 229 patients with LGL leukemia (201 patients with T-LGL) reported an overall response rate of 21 percent (4 percent complete) in 24 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (5 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO in two divided doses for at least three months, adjusted to a therapeutic blood level of 200 to 400",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      was given to 25 subjects with anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neutropenia associated with T-LGL leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/22\">",
"       22",
"      </a>",
"      ]. Fourteen patients responded with sustained improvement in neutrophil counts or transfusion independence, seven of whom had complete normalization of blood counts. On multivariate analysis the presence of HLA-DR4 was highly predictive of response to cyclosporine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (initial dose 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      PO every 12 hours), with or without low dose GM-CSF, has led to a return of normal neutrophil counts in five severely neutropenic subjects with initial absolute neutrophil counts",
"      <span class=\"nowrap\">",
"       &lt;500/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Abnormal LGL populations persisted in these patients and neutropenia returned when cyclosporine was discontinued. Two of these patients were able to maintain normal neutrophil levels for eight years with continuous cyclosporine therapy.",
"     </li>",
"     <li>",
"      In one study, clonal cytogenetic abnormalities were associated with a poor response to immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/18\">",
"       18",
"      </a>",
"      ]. However, five patients were successfully treated, with starting doses of 12",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses for four patients, and 150 mg twice daily for the remaining patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can be continued long-term, but its use is limited by drug interactions and side effects. Cyclosporine is metabolized by the hepatic cytochrome P450 3A enzymes and has a variety of important drug interactions. Toxicities with long-term use include gastrointestinal distress, nephrotoxicity, hypertension, neurotoxicity, and secondary malignancies. Blood pressure, creatinine, BUN, blood glucose, liver function tests, potassium and magnesium should be monitored every two weeks for the first three months of therapy, and every one to two months thereafter. Plasma creatinine is adequate for follow-up of the renal function; an increase above baseline by more than 30 percent (even if it is still in the normal range) requires a decrease of the dose or a temporary discontinuation of the drug. Similarly, hypertension during therapy should prompt reduction in dosage or initiation of anti-hypertensive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147328393\">",
"    <span class=\"h1\">",
"     RESPONSE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four months following the initiation of therapy, the response to treatment should be evaluated by history, physical examination, and complete blood count with differential [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response &mdash; A hematologic complete response is defined as the complete normalization of blood counts (ie, hemoglobin &gt;12",
"      <span class=\"nowrap\">",
"       g/dL;",
"      </span>",
"      platelets",
"      <span class=\"nowrap\">",
"       &gt;150,000/microL;",
"      </span>",
"      absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;1500/microL;",
"      </span>",
"      lymphocytosis",
"      <span class=\"nowrap\">",
"       &lt;4000/microL)",
"      </span>",
"      in the setting of a circulating LGL count of less than",
"      <span class=\"nowrap\">",
"       500/microL.",
"      </span>",
"     </li>",
"     <li>",
"      Partial response &mdash; A hematologic partial response is defined as an improvement in blood counts that does not meet criteria for complete remission (eg, an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"      or decreasing transfusion requirements).",
"     </li>",
"     <li>",
"      Treatment failure &mdash; Treatment failure is defined as an inability to achieve an at least partial response after four months of therapy.",
"     </li>",
"     <li>",
"      Progressive disease &mdash; Progressive disease is defined as a worsening of cytopenias, hepatomegaly, or splenomegaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who achieve an at least partial response should continue treatment until treatment failure or until the maximum number of months has elapsed for that regimen, whichever is shorter.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can be continued indefinitely, as tolerated. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should not be administered for longer than 6 to 12 months for responders. Patients who fail to attain an at least partial response should be considered for a new therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147331490\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED OR RESISTANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with relapsed, resistant, or refractory disease depends upon the initial treatment regimen and the timing of progression. For our purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relapsed disease refers to the progression of disease after an initial response.",
"     </li>",
"     <li>",
"      Resistant disease refers to the inability to achieve an at least partial response after four months of therapy.",
"     </li>",
"     <li>",
"      Refractory disease refers to the failure of the three major immunosuppressive drugs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35829953\">",
"    <span class=\"h2\">",
"     Relapsed disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with LGL leukemia that relapses after an initial response depends upon the timing of relapse. Patients not receiving active treatment at the time of relapse may respond to a second trial of the initial treatment regimen. More commonly, such patients and those who relapse on active therapy may respond to a trial of another one of the three major immunosuppressive drugs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Initial treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35829961\">",
"    <span class=\"h2\">",
"     Resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with LGL leukemia that is refractory to initial treatment should undergo a trial of another one of the three major immunosuppressive drugs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). As described above, responses to cyclophosphamide have been reported in a majority of patients who have failed treatment with methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/10\">",
"     10",
"    </a>",
"    ]. Some experts prefer cyclosporine for the treatment of patients with resistant disease manifesting as anemia. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Initial treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35830014\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory disease refers to those patients who have persistent LGL leukemia despite trials of the three major immunosuppressive drugs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). The optimal treatment of such patients is unknown and often the best option is to enroll in a clinical trial. Purine analogs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    have demonstrated activity in LGL leukemia and may be considered. Splenectomy may correct neutropenia, hemolytic anemia, or provide symptomatic relief from splenomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147331534\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    targets CD52 expressed on the surface of T-cell LGL leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/26\">",
"     26",
"    </a>",
"    ]. Case reports and small case series have demonstrated an overall response in approximately 50 percent of patients with refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/10,13,23,27-33\">",
"     10,13,23,27-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    are immunocompromised and are therefore at risk for potentially lethal opportunistic infections with organisms such as Pneumocystis jirovecii (previously Pneumocystis carinii) and cytomegalovirus. All patients planning to receive alemtuzumab should undergo serology testing for cytomegalovirus (IgM and IgG), herpes simplex virus (IgM and IgG), hepatitis B (HBsAg and anti-HBc), and hepatitis C (anti-HCV). While prophylaxis for such infections is generally given, clinicians need to consider these organisms when patients become unwell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35830215\">",
"    <span class=\"h3\">",
"     Purine analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the efficacy of purine analogs (eg, 2-chlorodeoxyadenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ) for the treatment of LGL leukemia are limited to less than 100 published cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/9,10,13,23,34-40\">",
"     9,10,13,23,34-40",
"    </a>",
"    ]. The overall response rate in reported cases is approximately 80 percent with most remission occurring after the first course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"     5",
"    </a>",
"    ]. Remissions lasting up to six years have been reported.",
"   </p>",
"   <p>",
"    Patients receiving therapy with purine analogs are at increased risk for several opportunistic infections. The use of antimicrobials in these patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35830444\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and small case series of patients with LGL leukemia have noted responses in up to 56 percent, with the most recent case series demonstrating low response rates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3,5,10,14,41-45\">",
"     3,5,10,14,41-45",
"    </a>",
"    ]. Splenectomy may be considered for patients with resistant disease who have symptomatic splenomegaly or evidence of autoimmune cytopenias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35829696\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the use of other treatment regimens for LGL leukemia. While occasional responses have been noted in case reports, more aggressive treatment, such as the use of allogeneic hematopoietic cell transplantation or chemotherapy regimens used for more aggressive lymphomas (eg, CHOP or hyper-CVAD), has had disappointing results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/1,46,47\">",
"     1,46,47",
"    </a>",
"    ]. Response rates with these regimens are poor and most patients die within one year after the start of treatment. One possible reason for the adverse outcome is that LGL leukemic cells, like their normal counterparts (NK or T cell cytotoxic cells), constitutively express high levels of P glycoprotein (PgP), the product of the multidrug resistance gene (MDR1) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/48-51\">",
"     48-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147330155\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGL leukemia is usually a chronic disease, and some patients may be asymptomatic for long periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/52\">",
"     52",
"    </a>",
"    ]. The first large series published in the literature included 151 patients; survival was approximately 85 percent at a mean follow-up of two to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/52\">",
"     52",
"    </a>",
"    ]. Another study of 68 patients reported a median survival greater than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multivariate analyses, risk factors associated with poor clinical outcome were fever at diagnosis, low percentage of CD57+ cells and low",
"    <span class=\"nowrap\">",
"     (&lt;5000/microL)",
"    </span>",
"    or high",
"    <span class=\"nowrap\">",
"     (&gt;20,000/microL)",
"    </span>",
"    peripheral LGL counts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2793/abstract/52\">",
"     52",
"    </a>",
"    ]. In another study, severe neutropenia or \"B\" symptoms (ie, fever, weight loss, night sweats) were associated with a lower probability of complete remission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147329114\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large granular lymphocyte (LGL) leukemia is characterized by peripheral blood and marrow lymphocytic infiltration with clonal LGLs, splenomegaly, and cytopenias, most commonly neutropenia. &nbsp;LGL leukemia can arise from the clonal proliferation of LGLs of T-cell or NK-cell lineage. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Not all patients with LGL leukemia require treatment at the time of diagnosis. Among newly diagnosed patients with asymptomatic T-LGL, we suggest close observation rather than immediate treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment is reserved for patients with symptoms due to neutropenia, anemia, or thrombocytopenia, and for patients with associated autoimmune conditions requiring therapy. (See",
"      <a class=\"local\" href=\"#H1147328340\">",
"       'Indications for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1147328348\">",
"       'Management of asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no agreed upon standard treatment regimen for symptomatic LGL leukemia, but there is general agreement that immunosuppressive therapy (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) is the cornerstone of initial treatment. A choice among immunosuppressive treatments is primarily made based upon the clinical setting and physician experience:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neutropenia &mdash; For patients with LGL leukemia and neutropenia as their primary symptom, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      rather than other immunosuppressive therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We administer oral methotrexate 10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly. For patients with an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &lt;200/microL,",
"      </span>",
"      oral prednisone (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) is administered in addition to the methotrexate for the first month and tapered off by the end of the second month. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune disorders &mdash; For patients with LGL leukemia and an associated autoimmune disorder, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In this setting, the use of prednisone is dictated by the accompanying autoimmune disorder. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anemia &mdash; For patients with LGL leukemia and anemia as their primary symptom, we suggest either oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While both of these agents have demonstrated activity in this setting, some clinicians prefer cyclophosphamide for patients with anemia at least partially due to its demonstrated activity in patients with pure red cell aplasia. Other clinicians prefer methotrexate because it can be continued indefinitely as long as it is tolerated, whereas treatment with oral cyclophosphamide is limited to no more than 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H35829049\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four months following the initiation of therapy, the response to treatment should be evaluated by history, physical examination, and complete blood count with differential. Patients who achieve an at least partial response should continue treatment until treatment failure or until the maximum number of months has elapsed for that regimen, whichever is shorter.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      can be continued indefinitely, as tolerated. In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      should not be administered for longer than 6 to 12 months for responders. (See",
"      <a class=\"local\" href=\"#H1147328393\">",
"       'Response evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of patients with relapsed, resistant, or refractory disease depends upon the initial treatment regimen and the timing of progression. (See",
"      <a class=\"local\" href=\"#H1147331490\">",
"       'Treatment of relapsed or resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/1\">",
"      Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/2\">",
"      Lamy T, Loughran TP Jr. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/3\">",
"      Dhodapkar MV, Li CY, Lust JA, et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994; 84:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/4\">",
"      Lamy T, LePrise PY, Amiot L, et al. Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia. Blood 1995; 85:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/5\">",
"      Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/6\">",
"      Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/7\">",
"      Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol 2011; 152:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/8\">",
"      Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/9\">",
"      Osuji N, Matutes E, Tjonnfjord G, et al. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer 2006; 107:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/10\">",
"      Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/11\">",
"      Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/12\">",
"      Hamidou MA, Sadr FB, Lamy T, et al. Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am J Med 2000; 108:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/13\">",
"      Fortune AF, Kelly K, Sargent J, et al. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma 2010; 51:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/14\">",
"      Mohan SR, Maciejewski JP. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol 2009; 16:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/15\">",
"      Loughran TP, Yao X, Bennett JM, et al. Results of a prospective multicenter phase II study of initial treatment with methotrexate in LGL leukemia (ECOG Protocol E5998) (abstract 702). Blood 2010; 116:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/16\">",
"      Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood 2001; 98:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/17\">",
"      Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/18\">",
"      Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/19\">",
"      Go RS, Lust JA, Phyliky RL. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Semin Hematol 2003; 40:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/20\">",
"      Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood 1996; 87:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/21\">",
"      Sood R, Stewart CC, Aplan PD, et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998; 91:3372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/22\">",
"      Battiwalla M, Melenhorst J, Saunthararajah Y, et al. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol 2003; 123:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/23\">",
"      Aribi A, Huh Y, Keating M, et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res 2007; 31:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/24\">",
"      Pawarode A, Wallace PK, Ford LA, et al. Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. Leuk Lymphoma 2010; 51:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/25\">",
"      Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol 1996; 93:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/26\">",
"      Osuji N, Del Giudice I, Matutes E, et al. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab. Leuk Lymphoma 2005; 46:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/27\">",
"      Mohan SR, Clemente MJ, Afable M, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009; 94:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/28\">",
"      Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/29\">",
"      Rosenblum MD, LaBelle JL, Chang CC, et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood 2004; 103:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/30\">",
"      Sch&uuml;tzinger C, Gaiger A, Thalhammer R, et al. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005; 19:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/31\">",
"      Au WY, Lam CC, Chim CS, et al. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005; 29:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/32\">",
"      Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009; 27:5425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/33\">",
"      Monjanel H, Hourioux C, Arbion F, et al. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Leuk Res 2010; 34:e197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/34\">",
"      Sternberg A, Eagleton H, Pillai N, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol 2003; 120:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/35\">",
"      Edelman MJ, O'Donnell RT, Meadows I. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol 1997; 54:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/36\">",
"      Ma SY, Au WY, Chim CS, et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol 2004; 124:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/37\">",
"      Tsirigotis P, Venetis E, Kapsimali V, et al. 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leuk Res 2003; 27:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/38\">",
"      Tse E, Chan JC, Pang A, et al. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia 2007; 21:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/39\">",
"      Dincol G, Diz-Ku&ccedil;ukkaya R, Bicakci E. T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin. Neth J Med 2008; 66:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/40\">",
"      Sretenovic A, Antic D, Jankovic S, et al. T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience. Med Oncol 2010; 27:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/41\">",
"      Subbiah V, Viny AD, Rosenblatt S, et al. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol 2008; 36:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/42\">",
"      Gentile TC, Hadlock KG, Uner AH, et al. Large granular lymphocyte leukaemia occurring after renal transplantation. Br J Haematol 1998; 101:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/43\">",
"      Loughran TP Jr, Starkebaum G, Clark E, et al. Evaluation of splenectomy in large granular lymphocyte leukaemia. Br J Haematol 1987; 67:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/44\">",
"      Furukawa Y, Tanaka K, Hasuike T, et al. [Chronic lymphocytic leukemia with peripheral T lymphocytes expressing CD 2+, CD 3+, CD 4-, CD 8-, CD 16+, and CD 56+ and lymph-node lymphocytes expressing CD 2+, CD 3-, CD 4-, CD 8-, CD 16+, CD 38+, and CD 56+]. Rinsho Byori 1991; 39:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/45\">",
"      Brinkman K, van Dongen JJ, van Lom K, et al. Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies. Leukemia 1998; 12:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/46\">",
"      Alekshun TJ, Tao J, Sokol L. Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol 2007; 82:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/47\">",
"      Seebach J, Speich R, Gm&uuml;r J. Allogeneic bone marrow transplantation for CD3+/TCR gamma delta+ large granular lymphocyte proliferation. Blood 1995; 85:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/48\">",
"      Lamy T, Drenou B, Fardel O, et al. Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol 1998; 100:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/49\">",
"      Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 1992; 12:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/50\">",
"      Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/51\">",
"      Yamamoto T, Iwasaki T, Watanabe N, et al. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood 1993; 81:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2793/abstract/52\">",
"      Pandolfi F, Loughran TP Jr, Starkebaum G, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 1990; 65:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4536 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2793=[""].join("\n");
var outline_f2_46_2793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147328340\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147328348\">",
"      MANAGEMENT OF ASYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147328356\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35829049\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147328393\">",
"      RESPONSE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147331490\">",
"      TREATMENT OF RELAPSED OR RESISTANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35829953\">",
"      Relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35829961\">",
"      Resistant disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35830014\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1147331534\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35830215\">",
"      - Purine analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35830444\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35829696\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147330155\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1147329114\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4536\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4536|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/1/28\" title=\"picture 1\">",
"      Large granular lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4536|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20040?source=related_link\">",
"      Natural killer (NK) cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_46_2794="Growth failure and poor weight gain in children with inflammatory bowel disease";
var content_f2_46_2794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth failure and poor weight gain in children with inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2794/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2794/contributors\">",
"     Jonathan E Teitelbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2794/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2794/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2794/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/46/2794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/46/2794/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/46/2794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure is the most common extraintestinal manifestation of inflammatory bowel disease (IBD) in children, and is particularly common among those with Crohn's disease (CD) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/1\">",
"     1",
"    </a>",
"    ]. The causes of growth failure are complex and include the inflammatory process itself, as well as malnutrition and perhaps treatment with glucocorticoids.",
"   </p>",
"   <p>",
"    The pathogenesis, evaluation, and treatment of growth failure or poor weight gain in children and adolescents with inflammatory bowel disease will be reviewed here. The assessment and management of micronutrient deficiencies in these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF GROWTH FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of factors contributes to the pathogenesis of growth failure in children with IBD, including inflammation, malnutrition, hypogonadism, and glucocorticoid treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that inflammation is an important mediator of growth failure in children with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/2\">",
"     2",
"    </a>",
"    ]. This notion is supported by observed improvements in linear growth that occur after a variety of treatments that reduce inflammation in IBD, including surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/3\">",
"     3",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], or exclusive enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The improvement in growth is independent of weight gain or reductions in corticosteroid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammation probably inhibits linear growth through proinflammatory cytokines, including interleukin 6 (IL-6). IL-6 inhibits insulin-like growth factor 1 (IGF-1), which modulates the physiologic effects of growth hormone in a pattern suggestive of growth hormone resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/2,9-11\">",
"     2,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important contributor to malnutrition in IBD is reduced nutrient intake. Other factors include malabsorption, maldigestion, increased energy requirements due to fever and inflammation, gastrointestinal protein loss, and the energy cost of growth. The effects of malnutrition on growth are mediated in part by insulin-like growth factor-1 (IGF-1) but through different mechanisms than those triggered by inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Reduced nutrient intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with IBD often ingest less dietary energy than healthy children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/8\">",
"     8",
"    </a>",
"    ]. The cause is probably multifactorial. Contributing factors include anorexia (perhaps due to tumor necrosis factor-alpha), the learned association of food with abdominal pain or diarrhea, early satiety (possibly related to decreased gastric emptying), and altered taste (perhaps due to concomitant zinc deficiency or medications, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/59/21425?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In addition, patients with IBD are sometimes counseled to avoid certain foods that may exacerbate symptoms, such as fiber in patients with intestinal strictures, or dairy products in patients with concomitant lactose intolerance.",
"   </p>",
"   <p>",
"    Nutrient intake may be particularly low during acute exacerbations of IBD. In one study, children acutely ill with IBD consumed 40 to 80 percent of their estimated needs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbohydrate malabsorption is present in some children with active CD. As an example, less than 30 percent of children with IBD have normal lactose absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/17\">",
"     17",
"    </a>",
"    ]. This is probably due to small bowel inflammation and enterocyte damage, or bacterial overgrowth.",
"   </p>",
"   <p>",
"    Intolerance to lactose is more common among adults with CD than in the general population, occurring in as many as 40 percent of adults from ethnic groups at low risk for lactose malabsorption, particularly in those with extensive disease in the small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In contrast, the prevalence of lactose intolerance in adults with ulcerative colitis (UC) is similar to that in controls of similar ethnic backgrounds [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, fat malabsorption was seen in approximately 30 percent of patients with CD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The cause is multifactorial, including small bowel inflammation, decreased bowel length due to surgery, bacterial overgrowth, bile acid deficiency due to disease or resection of the terminal ileum, and use of medicines such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"     cholestyramine",
"    </a>",
"    that bind bile acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Maldigestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maldigestion (impaired processing of nutrients within the lumen of the gastrointestinal tract) is unusual in patients with IBD but can occur among patients with Crohn's disease (CD) who have extensive mucosal disease or enteroenteric fistulas. In this setting, ingested nutrients may have insufficient exposure to digestive secretions and enzymes, leading to maldigestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Energy expenditure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resting energy expenditure (REE) in well-nourished children with CD is not different from values in healthy children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/13,24\">",
"     13,24",
"    </a>",
"    ]; the apparent increase in REE in children with CD is a result of their lower fat-free mass [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. REE is increased in children with mildly active CD, and correlates with disease activity. In well-nourished children who underwent ileocolectomy for CD, REE decreased approximately 5 percent after accounting for the energy expended by the resected intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased energy expenditure in active IBD may be mediated by proinflammatory cytokines. A lipid oxidation rate greater than normal has been demonstrated in adults with active CD, and this increase appears to correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In children, carbohydrate oxidation decreases and lipid oxidation increases without any change in energy expenditure after the first dose of a biological therapy to reduce inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated levels of cytokines (eg, tumor necrosis factor alpha [TNF-alpha]) are thought to mediate growth failure in CD. Although anti-TNF-alpha antibodies reduce disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/29\">",
"     29",
"    </a>",
"    ], a direct association between TNF-alpha and growth failure remains elusive. Animal studies support a role for interleukin-6 on growth delay by reducing IGF-1 production [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/30\">",
"     30",
"    </a>",
"    ] and stimulating lipolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Enteral protein loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary leak within inflamed tissue may result in protein loss. This is the main cause of reduced serum albumin concentrations that are commonly seen in active CD, and to a lesser extent in ulcerative colitis. Fecal alpha 1 antitrypsin serves as a measure of intestinal protein loss, and is increased in children with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Protein depletion is associated with a worse outcome after surgery in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucocorticoid treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids may contribute to growth failure, particularly when used during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Glucocorticoids interfere with endogenous growth hormone secretion and action, and disrupt metabolic processes essential for normal growth, including bone formation, nitrogen retention, and collagen formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of short stature\", section on 'Glucocorticoid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism and pubertal delay are common in children with active IBD. As a result, these individuals have decreased linear growth and delayed accretion of lean body mass compared to healthy children of the same age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Pubertal delay'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because children with pubertal delay usually have delayed bone age, some catch-up growth is possible after the onset of puberty. However, growth during puberty may also be compromised in those with prolonged inflammatory disease, malnutrition, or corticosteroid therapy, so adult height may be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Short stature'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Inflammatory processes and malnutrition probably both contribute to hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/38\">",
"     38",
"    </a>",
"    ]. Proinflammatory cytokines directly reduce gonadal sex steroid production and, perhaps, also androgen and estrogen receptor expression in peripheral tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/2,39,40\">",
"     2,39,40",
"    </a>",
"    ]. In addition, healthy body weight is an important prerequisite for the onset of puberty. Leptin levels, which are proportionate to body fat, must be sufficient for maturation of the gonadotropin-releasing hormone (GnRH) axis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link&amp;anchor=H11#H11\">",
"     \"Normal puberty\", section on 'Body fat, leptin, and onset of puberty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL CONSEQUENCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Short stature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear growth is easily disrupted by inflammation and malnutrition, and growth failure is common in children with IBD. In a population-based study from the United Kingdom, 13 percent of patients with CD and 3 percent of those with UC had heights less than the third percentile at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/41\">",
"     41",
"    </a>",
"    ]. In a population-based study from France, 9.5 percent of children with CD had growth failure and 32 percent had severe malnutrition (defined as height and BMI less than -2 SD [&lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile], respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/42\">",
"     42",
"    </a>",
"    ]. During a mean follow-up of 6 years, growth retardation persisted in nearly 7 percent of patients and malnutrition in 15 percent of patients, despite treatment. Male gender and younger age at diagnosis were associated with short stature at follow-up. It should be noted that this study took place between 1988 and 2004, and the clinical care included more frequent use of corticosteroids and less frequent and later use of biologic agents than is typical in the current era. Thus, this study population probably does not reflect the beneficial effects of biologic agents such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    on height velocity. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Immunomodulators'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Serial measurements of height (height velocity) are a particularly sensitive indicator of disease activity or malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/43\">",
"     43",
"    </a>",
"    ]. Reduced height velocity is present at diagnosis in up to 88 percent of children with CD, and marked growth delays occur in 20 to 30 percent at some time during their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Five percent of children presenting with CD will have growth failure as their sole presenting complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Height velocity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Disruptions of linear growth during childhood probably lead to reduced adult stature in a substantial number of individuals with CD. A study of young adults diagnosed with CD prior to age 16 calculated a height deficit of 2.4 cm as compared to estimated target heights, and for almost 20 percent of the subjects the height deficit was more than 8 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/47\">",
"     47",
"    </a>",
"    ]. However, another study that assessed adult height in patients with CD found that the apparent deficit in adult height in patients with early onset CD was not significant, once adjustment was made for parental heights [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pubertal delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pubertal delay is common in IBD, and depends on the age of onset of IBD. In one series of 11 women with early onset CD, 75 percent had menarche at 16 years of age or later, but pubertal delay was much less common for children with UC [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/48\">",
"     48",
"    </a>",
"    ]. Other series report average delays in puberty onset about 1.5 years for girls and 0.8 years for boys [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/37,49\">",
"     37,49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Hypogonadism'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Poor weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;IBD is associated with impaired weight gain, which may be present even early in the course of the disease. A large study of North American children with IBD found that 22 to 24 percent of children with CD and 7 to 9 percent of those with UC had a low BMI (&lt;5th percentile) at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/50\">",
"     50",
"    </a>",
"    ]. However, 10 percent of children with CD and 20 to 30 percent of those with UC had an elevated BMI at diagnosis, reflecting current population trends in childhood obesity. In some cases, there is also acute weight loss. In an illustrative series, 58 percent of children with CD and 31 percent of those with UC had weight loss at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Reduced muscle mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of children and adults with CD have depleted protein stores (ie, lean body mass), particularly in the active phase of disease, and children with CD have less lean body mass than height-matched unaffected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/36,51,52\">",
"     36,51,52",
"    </a>",
"    ]. Patients who have lost between 5 and 10 percent of their lean body mass usually have no clinical sequelae. However, loss of lean body mass beyond this threshold is associated with increased morbidity. Children are particularly susceptible to these effects.",
"   </p>",
"   <p>",
"    The primary mediators of this effect are inflammation (excessive catabolism, which accelerates protein breakdown), decreased physical activity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/53\">",
"     53",
"    </a>",
"    ]. Inadequate protein intake may also affect muscle mass in growing children. Studies of children with CD demonstrated that increased protein intake resulted in increased nitrogen retention, increased amino acid incorporation into body protein stores and decreased amino acid loss via oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. Low protein intake is less likely to cause reduced muscle mass in adults unless the deficiency is severe and prolonged (starvation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone disease (osteoporosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomalacia) is a common problem in adults with IBD, and the rate does not differ among patients with CD as compared with those with UC [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/55\">",
"     55",
"    </a>",
"    ]. Risk factors include corticosteroid use",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disease activity and age, as well as pubertal delay and possibly deficiencies of calcium and vitamins D and K [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Prevention and treatment of bone loss in IBD consists of attempting to reverse or minimize these factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children and adolescents with IBD also tend to have reduced bone mineral density (BMD) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This is more common among those with CD than those with UC, and may be present at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The evaluation and treatment of bone disease in children and adolescents differs from that in adults. Dual energy x-ray absorptiometry (DXA) scanning can be used to evaluate bone density in children, and the findings are expressed as Z-scores to reflect age-specific standards (rather than T-scores as in adults). However, interpretation remains problematic and requires adjustment for bone size; the unadjusted DXA Z-score for age and gender may systematically underestimate bone density in shorter patients or in patients with delay in growth and maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/59,63\">",
"     59,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no widely accepted standards for monitoring for bone disease in children with IBD, and practice is based on expert opinion with limited evidence. One group has suggested annual DXA scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/1\">",
"     1",
"    </a>",
"    ]. Another group suggests DXA scanning in children with IBD and risk factors for bone disease, including delays in linear growth or puberty, underweight, amenorrhea, severe inflammatory course of IBD, prolonged use of glucocorticoids, or history of clinically significant fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/58\">",
"     58",
"    </a>",
"    ]. The same group suggests repeating the scan annually if the BMD z-score is more than 1.0 SD below the mean.",
"   </p>",
"   <p>",
"    In children and adolescents, it is unclear whether modest decreases in bone density predict fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/57\">",
"     57",
"    </a>",
"    ]. Thus, we suggest that treatment focus on minimizing risk factors for bone disease, by intensive counseling to optimize nutrition, addressing pubertal delay, and minimizing use of glucocorticoids. The recommended intake of vitamin D and calcium are the same as those for healthy children: vitamin D is 600 int. units (IU) for all ages, and calcium is 1300 mg daily for adolescents, and 1000 mg daily for younger children. Many children require supplements to meet these goals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/59\">",
"     59",
"    </a>",
"    ]. One guideline suggests higher intake of both of these nutrients in children and adolescents with IBD: targeting vitamin D intake of 800 to 1000 int. units, and calcium intake of 1000 to 1600 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/58\">",
"     58",
"    </a>",
"    ]. Monitoring of serum concentrations of 25-hydroxyvitamin D (25OHD) is recommended at least annually [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/59\">",
"     59",
"    </a>",
"    ]. Additional vitamin D supplements should be given as needed to maintain 25OHD levels in a healthy range. Optimal 25OHD levels have not been established for children, but most authorities recommend maintaining 25OHD levels &ge;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are increasing concerns about the use of bisphosphonates in children because these agents form bone with abnormal characteristics, have extremely long half-lives, and the long-term risks and benefits have not been fully explored [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/58,64\">",
"     58,64",
"    </a>",
"    ]. Thus, these drugs are generally reserved for pediatric patients with severe reductions in BMD and pathological extremity fractures or vertebral compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Postoperative morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is associated with poor wound healing and increased susceptibility to infection following surgery in adult patients with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/34,65\">",
"     34,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Psychosocial stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety and depression in adult patients with IBD are correlated with both malnutrition and physical morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/66\">",
"     66",
"    </a>",
"    ]. Similarly, decreased self esteem, school, and social performance have been attributed to malnutrition in children with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     NUTRITIONAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional assessment is essential for the care of patients with IBD, particularly those in the pediatric age range. Prompt recognition of reduced height velocity in children with IBD allows for intervention to optimize nutrition and address the inflammatory disease, and may prevent permanent growth failure. Growth parameters should be monitored in all children. Further evaluation is indicated in those with growth failure, as discussed below. Evaluation for specific micronutrient deficiencies depends on risks, as determined by overall nutritional status and disease activity and location, which is discussed in a separate topic review (",
"    <a class=\"graphic graphic_table graphicRef73559 \" href=\"UTD.htm?42/41/43675\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Growth parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;All children with inflammatory bowel disease should have regular measurements of body weight, height, and pubertal status [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/1,43\">",
"     1,43",
"    </a>",
"    ]. Body mass index (BMI) for age and height velocity should be calculated. In our practice we perform these measurements at least every four months for patients with quiescent disease, and more frequently for those with active disease or evidence of growth failure (",
"    <a class=\"graphic graphic_table graphicRef61093 \" href=\"UTD.htm?3/50/3885\">",
"     table 2",
"    </a>",
"    ). Referral to a specialist in nutrition can be helpful, particularly in severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Height velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced linear growth is often first noted by a decreasing trend in height percentiles on a standard height-for-age chart. Height percentiles should also be interpreted in the context of the child's genetic potential, usually estimated based on the midparental height. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to short stature\", section on 'Prediction of height potential'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Height velocity measurements are the most sensitive parameter for detection of growth abnormalities during IBD in children [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/43,45\">",
"     43,45",
"    </a>",
"    ]. Height velocity can be calculated from two or more serial measurements of height, ideally taken three to six months apart and expressed as growth in",
"    <span class=\"nowrap\">",
"     cm/year.",
"    </span>",
"    Any child older than two years whose height velocity is less than 4",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    probably has growth failure, because at least 95 percent of healthy children grow faster than 4",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/67\">",
"     67",
"    </a>",
"    ]. During puberty, peak height velocity is 5 to 11",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    in boys, and 6 to 10",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    in girls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H13#H13\">",
"     \"Measurement of growth in children\", section on 'Growth velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To determine if a child's height velocity is appropriate for age, height velocity can be plotted on a standard curve (",
"    <a class=\"graphic graphic_figure graphicRef66909 graphicRef74573 \" href=\"UTD.htm?32/1/32792\">",
"     figure 1A-B",
"    </a>",
"    ). No specific thresholds for intervention have been established, but we suggest that children with IBD and height velocity below the 10th percentile should be assessed for nutritional deficits, and more intensive nutritional intervention or change in IBD therapy should be considered. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Body mass index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-specific percentiles for BMI are determined by plotting on a standard chart (",
"    <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"UTD.htm?10/0/10247\">",
"     figure 2A-B",
"    </a>",
"    ) or by using a calculator for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). The usual threshold for defining underweight is a BMI below the 5th percentile for age, but this cutoff is insufficient for identifying growth abnormalities in children with IBD. Instead, we suggest that progressive decreases in BMI percentiles, or a BMI below the 10th percentile for age should prompt evaluation and nutritional intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dietary intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of dietary intake for three- to five-day periods helps to assess the total calories, protein, and micronutrients consumed, and highlights nutrient deficiencies that may be associated with inadequate intake.",
"   </p>",
"   <p>",
"    In our practice, we generally analyze dietary intake in children who are not gaining weight appropriately and in whom it is unclear whether this is due to inadequate calories or malabsorption. However, most children who are not gaining weight appropriately report that they have no appetite and find it difficult to eat; thus, formal assessments rarely contribute to clinical decision-making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are markedly underweight (eg, BMI&lt;5th percentile for age), measures of body composition can help to characterize the severity. Techniques include triceps skin fold thickness measurements, which reflect body fat (",
"    <a class=\"graphic graphic_table graphicRef67683 \" href=\"UTD.htm?13/34/13871\">",
"     table 3",
"    </a>",
"    ) and mid-arm cross sectional area, which reflects lean body mass. Several other measures for determining body composition are available, including bioelectrical impedance analysis (BIA) and dual energy x-ray absorptiometry (DXA) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether any of these measures provides clinically important information that is any better than a simple visual assessment of muscle mass has not been established. The BMI measurement alone is usually a sufficient for clinical decision-making, so additional measurements of body composition usually are not usually necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=see_link\">",
"     \"Measurement of body composition in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimizing nutrition is an important step in managing growth failure. The intensity of the intervention can be adjusted to the severity of the growth failure.",
"   </p>",
"   <p>",
"    Effective treatment of the inflammatory process itself is also critical to restoring growth. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Inflammation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals with IBD should be given dietary advice to ensure a balanced diet with adequate calories to optimize growth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/43\">",
"     43",
"    </a>",
"    ]. For patients with active disease or malabsorption, energy intake goals will often be higher than for the general population. Children with growth failure also have increased energy requirements for catch-up growth, even if their IBD is inactive. Catch-up growth typically requires 125 to 150 percent of the recommended daily allowance for energy, and 2.4 to 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of protein [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To avoid unnecessary reduction of energy intake, dietary restrictions for patients with IBD should only be recommended when there is clear evidence of intolerance (eg, an abnormal lactose breath hydrogen test) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minimizing the use of glucocorticoids is appropriate in all patients to avoid growth failure and bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/1\">",
"     1",
"    </a>",
"    ]. These adverse effects of glucocorticoids must be balanced against their potential therapeutic value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nutritional counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild growth failure (decreased height velocity), the initial intervention is to provide more intensive dietary advice to increase energy intake, sometimes including liquid supplements taken by mouth. Calculations of energy requirements should be based on ideal body weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23735?source=see_link\">",
"     \"Dietary energy requirements in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small nonrandomized studies in children and adults support this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, the efficacy of nutritional counseling in IBD has not been carefully studied, and the energy and nutrient increases achieved through this approach are probably modest. Addition of a liquid supplement taken by mouth supplying 35 to 50 percent of estimated energy needs effectively promotes weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Supplemental enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with marked growth failure who are unable to increase their energy intake voluntarily may benefit from liquid nutritional supplements. This type of intensive nutritional intervention can help prevent or reverse the consequences of malnutrition, including growth failure, pubertal delay, and bone disease.",
"   </p>",
"   <p>",
"    When supplemental enteral feedings are used, the child usually eats freely during the day and then passes a nasogastric tube at night to administer formula while sleeping. Nutritional goals are generally from 100 to 150 percent of the recommended daily allowances for height-age for both energy (85 to 90",
"    <span class=\"nowrap\">",
"     kCal/kg",
"    </span>",
"    per day) and protein (2.4 to 3.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day); this usually translates to 1000 to 1500 kCals of formula nightly. We find that administering a set amount of formula is easiest and most successful, rather than adjusting the formula intake based on the voluntary intake of food. Deficiencies in vitamins and minerals should be assessed and replaced by supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/72\">",
"     72",
"    </a>",
"    ]. The type of formula used (elemental versus polymeric) is not important [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/43\">",
"     43",
"    </a>",
"    ]. This issue has been best examined in the setting of exclusive enteral nutrition, which is discussed below.",
"   </p>",
"   <p>",
"    In a small nonrandomized study of prepubertal children with CD, nocturnal feedings yielded a mean weight gain of 11.75 kg and a mean height gain of 6.98 cm over one year, whereas matched control subjects had no change in weight and height [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/73\">",
"     73",
"    </a>",
"    ]. Another study demonstrated that supplemental feeding administered as little as one month out of every four results in improved weight gain and height velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/74\">",
"     74",
"    </a>",
"    ]. A third study, performed retrospectively, suggested that use of supplementary nasogastric feeds during remission of IBD improved linear growth and prolonged remission [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/75\">",
"     75",
"    </a>",
"    ]. Improved intake of energy, calcium, and vitamin D is also an important step in treating bone disease, as discussed above. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Bone disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"     \"Nutrient deficiencies in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Exclusive enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral nutrition with no food taken by mouth, or exclusive enteral nutrition (EEN), can also be used as primary therapy for CD. Small randomized trials indicate that EEN suppresses inflammation, promotes mucosal healing, and reverses growth failure in children with IBD. This approach is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of the management of Crohn's disease in children and adolescents\", section on 'Exclusive enteral nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Immunomodulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective treatment of the inflammatory process itself is critical to restoring growth. The inflammatory disease may be occult, so marked growth failure should prompt a thorough evaluation and consideration of alternate strategies to treat the IBD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link\">",
"     \"Overview of the management of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children with marked growth failure, changing therapy to immunomodulators such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    can enhance growth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Similarly, in children with localized treatment-resistant CD, surgical resection of the inflamed bowel segment can be effective in restoring growth [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/3,76\">",
"     3,76",
"    </a>",
"    ]. A randomized trial of early treatment with 6-mercaptopurine did not show beneficial effects on growth as compared to conventional treatment with glucocorticoids, but the sample size was small, and the subjects had minimal growth retardation at randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21303?source=see_link\">",
"     infliximab",
"    </a>",
"    or other immunosuppressants are used, their efficacy in treating growth failure is probably more closely related to their anti-inflammatory effects rather than to reductions in corticosteroid use. This was suggested by the surgical study cited above that reversed growth failure while corticosteroid doses were kept constant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, effective treatment of the inflammatory process is a critical component of treatment for growth failure in IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few reports describe treatment of children with IBD and severe growth delay with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/61/3032?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    (rhGH) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/78-83\">",
"     78-83",
"    </a>",
"    ] or exogenous sex steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/46/2794/abstract/84\">",
"     84",
"    </a>",
"    ], but there is insufficient information to recommend for or against these approaches in this population. Until more information on these treatments is available, these treatments should be considered only after the IBD and nutrition have been optimized through intensive interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=see_link\">",
"       \"Patient information: Ulcerative colitis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disruption of linear growth is common in children with inflammatory bowel disease (IBD), particularly those with Crohn's disease (CD). Marked growth delays occur in 20 to 30 percent of children with CD; linear growth is highly sensitive to disease activity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Short stature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A combination of factors contributes to the pathogenesis of growth failure in IBD, including inadequate dietary intake, inflammation, malabsorption, glucocorticoids, and pubertal delay. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis of growth failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children with IBD should have regular measurements of body weight, height, and pubertal status. Body mass index (BMI) and height velocity should be calculated (",
"      <a class=\"graphic graphic_table graphicRef61093 \" href=\"UTD.htm?3/50/3885\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Growth parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with IBD whose height velocity (",
"      <a class=\"graphic graphic_figure graphicRef66909 graphicRef74573 \" href=\"UTD.htm?32/1/32792\">",
"       figure 1A-B",
"      </a>",
"      ) or BMI (",
"      <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"UTD.htm?10/0/10247\">",
"       figure 2A-B",
"      </a>",
"      ) is below the 10th percentile for age are probably experiencing growth failure due to their disease, and should be further assessed for nutritional deficits and apparent or occult IBD activity. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Nutritional assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children with IBD should be counseled to ensure a balanced diet with adequate dietary energy and nutrients to optimize growth. For patients with active disease or malabsorption, energy and nutrient goals will often be higher than for the general population. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intensive nutritional intervention or change in IBD therapy should be considered for children with IBD and growth failure. This may include focused nutritional counseling and the use of nutritional supplements to meet energy needs, or supplemental enteral nutrition given by nasogastric tube at night. Exclusive enteral nutrition or other strategies to suppress the inflammatory disease also have beneficial effects on growth. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/1\">",
"      Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/2\">",
"      Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr 2006; 43:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/3\">",
"      Varille V, C&eacute;zard JP, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1996; 23:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/4\">",
"      Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/5\">",
"      Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/6\">",
"      Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-&alpha; therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/7\">",
"      Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005; :CD003873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/8\">",
"      Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/9\">",
"      Bresson JL, Schmitz J. Malnutrition in Crohn's disease: substrate deficiency or misuse? Horm Res 1992; 38 Suppl 1:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/10\">",
"      Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/11\">",
"      Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A 2005; 102:13260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/12\">",
"      Hill KK, Hill DB, McClain MP, et al. Serum insulin-like growth factor-I concentrations in the recovery of patients with anorexia nervosa. J Am Coll Nutr 1993; 12:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/13\">",
"      Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/14\">",
"      Grill BB, Lange R, Markowitz R, et al. Delayed gastric emptying in children with Crohn's disease. J Clin Gastroenterol 1985; 7:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/15\">",
"      Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/16\">",
"      Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996; 12:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/17\">",
"      Kirschner BS, DeFavaro MV, Jensen W. Lactose malabsorption in children and adolescents with inflammatory bowel disease. Gastroenterology 1981; 81:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/18\">",
"      von Tirpitz C, Kohn C, Steinkamp M, et al. Lactose intolerance in active Crohn's disease: clinical value of duodenal lactase analysis. J Clin Gastroenterol 2002; 34:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/19\">",
"      Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol 1997; 92:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/20\">",
"      H&uuml;ppe D, Tromm A, Langhorst H, May B. [Lactose intolerance in chronic inflammatory bowel diseases]. Dtsch Med Wochenschr 1992; 117:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/21\">",
"      Perkal MF, Seashore JH. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/22\">",
"      Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn's disease in children and adolescents. Pediatrics 1975; 55:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/23\">",
"      Beeken WL. Absorptive defects in young people with regional enteritis. Pediatrics 1973; 52:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/24\">",
"      Chan AT, Fleming CR, O'Fallon WM, Huizenga KA. Estimated versus measured basal energy requirements in patients with Crohn's disease. Gastroenterology 1986; 91:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/25\">",
"      Zoli G, Katelaris PH, Garrow J, et al. Increased energy expenditure in growing adolescents with Crohn's disease. Dig Dis Sci 1996; 41:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/26\">",
"      Mingrone G, Capristo E, Greco AV, et al. Elevated diet-induced thermogenesis and lipid oxidation rate in Crohn disease. Am J Clin Nutr 1999; 69:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/27\">",
"      Al-Jaouni R, H&eacute;buterne X, Pouget I, Rampal P. Energy metabolism and substrate oxidation in patients with Crohn's disease. Nutrition 2000; 16:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/28\">",
"      Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. Pediatr Res 2008; 64:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/29\">",
"      Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/30\">",
"      De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/31\">",
"      Yang Y, Ju D, Zhang M, Yang G. Interleukin-6 stimulates lipolysis in porcine adipocytes. Endocrine 2008; 33:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/32\">",
"      Miura S, Yoshioka M, Tanaka S, et al. Faecal clearance of alpha 1-antitrypsin reflects disease activity and correlates with rapid turnover proteins in chronic inflammatory bowel disease. J Gastroenterol Hepatol 1991; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/33\">",
"      Griffiths AM, Drobnies A, Soldin SJ, Hamilton JR. Enteric protein loss measured by fecal alpha 1-antitrypsin clearance in the assessment of Crohn's disease activity: a study of children and adolescents. J Pediatr Gastroenterol Nutr 1986; 5:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/34\">",
"      Stokes MA. Crohn's disease and nutrition. Br J Surg 1992; 79:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/35\">",
"      Alemzadeh N, Rekers-Mombarg LT, Mearin ML, et al. Adult height in patients with early onset of Crohn's disease. Gut 2002; 51:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/36\">",
"      Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004; 19:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/37\">",
"      Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/38\">",
"      Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/39\">",
"      Hales DB, Diemer T, Hales KH. Role of cytokines in testicular function. Endocrine 1999; 10:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/40\">",
"      Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997; 37:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/41\">",
"      Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/42\">",
"      Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010; 105:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/43\">",
"      Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/44\">",
"      Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/45\">",
"      Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/46\">",
"      Booth IW. The nutritional consequences of gastrointestinal disease in adolescence. Acta Paediatr Scand Suppl 1991; 373:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/47\">",
"      Sawczenko A, Ballinger AB, Croft NM, et al. Adult height in patients with early onset of Crohn's disease. Gut 2003; 52:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/48\">",
"      Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ 1994; 308:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/49\">",
"      Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in pediatric patients with Crohn's disease. Dig Dis Sci 2012; 57:2975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/50\">",
"      Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/51\">",
"      Rocha R, Santana GO, Almeida N, Lyra AC. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr 2009; 101:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/52\">",
"      Motil KJ, Grand RJ, Maletskos CJ, Young VR. The effect of disease, drug, and diet on whole body protein metabolism in adolescents with Crohn disease and growth failure. J Pediatr 1982; 101:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/53\">",
"      Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003; 98:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/54\">",
"      Motil KJ, Grand RJ, Matthews DE, et al. Whole body leucine metabolism in adolescents with Crohn's disease and growth failure during nutritional supplementation. Gastroenterology 1982; 82:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/55\">",
"      Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/56\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/57\">",
"      Hill RJ, Brookes DS, Davies PS. Bones in pediatric Crohn's disease: a review of fracture risk in children and adults. Inflamm Bowel Dis 2011; 17:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/58\">",
"      Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/59\">",
"      Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/60\">",
"      Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/61\">",
"      Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/62\">",
"      Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009; 136:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/63\">",
"      Simpson DE, Dontu VS, Stephens SE, et al. Large variations occur in bone density measurements of children when using different software. Nucl Med Commun 2005; 26:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/64\">",
"      Marini JC. Do bisphosphonates make children's bones better or brittle? N Engl J Med 2003; 349:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/65\">",
"      Hill GL, Blackett RL, Pickford IR, Bradley JA. A survey of protein nutrition in patients with inflammatory bowel disease--a rational basis for nutritional therapy. Br J Surg 1977; 64:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/66\">",
"      Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997; 32:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/67\">",
"      Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/68\">",
"      Kirschner BS, Klich JR, Kalman SS, et al. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981; 80:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/69\">",
"      Imes S, Pinchbeck B, Thomson AB. Diet counselling improves the clinical course of patients with Crohn's disease. Digestion 1988; 39:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/70\">",
"      Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/71\">",
"      Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. Isr Med Assoc J 2008; 10:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/72\">",
"      Han PD, Burke A, Baldassano RN, et al. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/73\">",
"      Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989; 97:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/74\">",
"      Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/75\">",
"      Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/76\">",
"      McLain BI, Davidson PM, Stokes KB, Beasley SW. Growth after gut resection for Crohn's disease. Arch Dis Child 1990; 65:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/77\">",
"      Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/78\">",
"      Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 2005; 11:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/79\">",
"      Heyman MB, Garnett EA, Wojcicki J, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J Pediatr 2008; 153:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/80\">",
"      Wong SC, Hassan K, McGrogan P, et al. The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature. J Pediatr Endocrinol Metab 2007; 20:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/81\">",
"      Wong SC, Kumar P, Galloway PJ, et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. Clin Endocrinol (Oxf) 2011; 74:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/82\">",
"      Denson LA, Kim MO, Bezold R, et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010; 51:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/83\">",
"      Vortia E, Kay M, Wyllie R. The role of growth hormone and insulin-like growth factor-1 in Crohn's disease: implications for therapeutic use of human growth hormone in pediatric patients. Curr Opin Pediatr 2011; 23:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/46/2794/abstract/84\">",
"      Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003; 53:205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5893 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-3C9D172F08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2794=[""].join("\n");
var outline_f2_46_2794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS OF GROWTH FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Reduced nutrient intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Malabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Maldigestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Energy expenditure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Enteral protein loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucocorticoid treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Short stature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pubertal delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Poor weight gain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Reduced muscle mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Postoperative morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Psychosocial stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      NUTRITIONAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Growth parameters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Height velocity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Body mass index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dietary intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Body composition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nutritional counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Supplemental enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Exclusive enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Immunomodulators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5893|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4692\" title=\"figure 1A\">",
"      Height velocity in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16387\" title=\"figure 1B\">",
"      Height velocity in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/23/38257\" title=\"figure 2A\">",
"      CDC BMI for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40993\" title=\"figure 2B\">",
"      CDC BMI for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/41/43675\" title=\"table 1\">",
"      Nutritional assess children IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/50/3885\" title=\"table 2\">",
"      IBD nutr monitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/34/13871\" title=\"table 3\">",
"      Triceps skin fold normals",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23735?source=related_link\">",
"      Dietary energy requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6760?source=related_link\">",
"      Measurement of body composition in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=related_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=related_link\">",
"      Patient information: Ulcerative colitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_46_2795="Non HDL cholesterol goals";
var content_f2_46_2795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Non-HDL-cholesterol goals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-HDL-cholesterol goal, mg/dL (mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary heart disease (CHD) or equivalent (10- year risk of CHD &gt;20 percent)",
"       </td>",
"       <td>",
"        &lt;130 (3.36)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more CHD risk factors and 10-year risk of CHD &le;20 percent",
"       </td>",
"       <td>",
"        &lt;160 (4.13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 1 CHD risk factor",
"       </td>",
"       <td>",
"        &lt;190 (4.91)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2795=[""].join("\n");
var outline_f2_46_2795=null;
var title_f2_46_2796="DSM-IV-TR diagnostic criteria for bulimia nervosa";
var content_f2_46_2796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for bulimia nervosa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eating, in a discrete period of time (eg, within any two-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        A sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent inappropriate compensatory behavior to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, enemas,&nbsp;or other medications; fasting; or excessive exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The binge eating and inappropriate compensatory behaviors both occur, on average, at least twice a week for three months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-evaluation is unduly influenced by body shape and weight.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The disturbance does not occur exclusively during episodes of anorexia nervosa.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Specify type:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Purging type: during the current episode of bulimia nervosa, the person has regularly engaged in self-induced vomiting or the misuse of laxatives,&nbsp;diuretics, or enemas.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonpurging type: during the current episode of bulimia nervosa, the person has used other inappropriate compensatory behaviors, such as fasting or excessive exercise, but has not&nbsp;regularly engaged in self-induced vomiting or the misuse of laxatives,&nbsp;diuretics, or enemas.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC,&nbsp;American Psychiatric Association, 2000, p. 594.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2796=[""].join("\n");
var outline_f2_46_2796=null;
var title_f2_46_2797="Management of life-threatening acute respiratory compromise";
var content_f2_46_2797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of life-threatening causes of acute respiratory compromise in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maneuver",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete upper airway obstruction*",
"       </td>",
"       <td>",
"        Needle cricothyrotomy",
"       </td>",
"       <td>",
"        This is a temporizing measure that can provide oxygenation, but not ventilation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Foreign body",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Back blows/chest thrusts (&lt;1 year of age)",
"       </td>",
"       <td>",
"        Maneuvers should only be used for patients who are unable to phonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal thrusts (&ge;1 year of age)",
"       </td>",
"       <td>",
"        Maneuvers should only be used for patients who are unable to phonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manual removal with finger sweep",
"       </td>",
"       <td>",
"        Perform this maneuver only when foreign body is visible in the oropharynx",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngoscopy and removal with Magill forceps",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Laryngospasm",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Positive pressure with a ventilation bag and tight fitting mask",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Soft tissue upper airway obstruction",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Head tilt/chin lift",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaw thrust",
"       </td>",
"       <td>",
"        Use for patients who may have cervical spine injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nasopharyngeal airway",
"       </td>",
"       <td>",
"        May be tolerated by a conscious patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oropharyngeal airway",
"       </td>",
"       <td>",
"        Use only in an unconscious patient",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Respiratory failure",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Bag-mask ventilation",
"       </td>",
"       <td>",
"        Suspect upper airway obstruction if unable to ventilate with proper size equipment and technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endotracheal intubation",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Use for patient who requires more than a few minutes of assisted ventilation or those with complete subglottic upper airway obstruction",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tension pneumothorax",
"       </td>",
"       <td>",
"        Needle thoracentesis",
"       </td>",
"       <td>",
"        Patients will require chest tube placement following emergent decompression",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cardiac tamponade",
"       </td>",
"       <td>",
"        Pericardiocentesis",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See topic on \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\".",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      See topic on \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Suspected foreign body'.",
"      <br>",
"       &Delta; See topic on \"Basic airway management in children\".",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        See topic on \"Emergent endotracheal intubation in children\".",
"        <br>",
"         &sect; See topic on \"Emergency pericardiocentesis\".",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2797=[""].join("\n");
var outline_f2_46_2797=null;
var title_f2_46_2798="ACC AHA manage high risk for HF";
var content_f2_46_2798=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75241%7ECARD%2F67792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75241%7ECARD%2F67792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Prevention of chronic heart failure (HF): Patients at high risk of developing HF (stage A)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of patients at high risk of developing HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; The following problems should be treated according to recommended guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Systolic and diastolic hypertension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Lipid disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Blood glucose control in diabetes mellitus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. The above and other secondary prevention measures in patients with atherosclerotic vascular disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Thyroid disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Avoidance of behaviors that may increase the risk of HF, such as smoking, excessive alcohol consumption, and illicit drug use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; The ventricular rate should be controlled or sinus rhythm restored in patients with supraventricular tachyarrhythmias.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Periodic evaluation for signs and symptoms of HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Noninvasive determination of left ventricular ejection fraction in patients with a strong family history of cardiomyopathy or those treated with cardiotoxic interventions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach for the management of patients at high risk of developing HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers to prevent HF in patients at high risk for developing HF due to a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension with associated cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Angiotensin II receptor blockers can be useful to prevent HF in patients at high risk for developing HF who have a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension with associated cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approach is not useful or may be harmful in the management of patients at high risk of developing HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Routine use of nutritional supplements solely to prevent the development of structural heart disease.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt, SA, Abraham, WT, Chin, MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management of patients with asymptomatic left ventricular (LV) dysfunction or hypertrophy (heart failure stage B)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Beta blockers and angiotensin converting enzyme (ACE) inhibitors if there is a recent or remote history of myocardial infarction (MI), regardless of left ventricular ejection fraction (LVEF).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; An angiotensin II receptor blocker (ARB) to post-MI patients who do not tolerate an ACE inhibitor and have a low LVEF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Beta blockers and ACE inhibitors in patients without a history of MI who have a reduced LVEF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Treatment of an acute MI according to current guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Coronary revascularization according to current guidelines.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Valve replacement or repair for hemodynamically significant valvular stenosis or regurgitation according to current guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approaches for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; ACE inhibitors or ARBs in patients with hypertension and LV hypertrophy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; ARBs in patients with a low LVEF who are intolerant of ACE inhibitors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Placement of an ICD in patients with ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF of &le;30 percent, are NYHA functional class I on chronic optimal medical therapy, and have a reasonable expectation of survival with a good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approach for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Placement of an ICD in patients with nonischemic cardiomyopathy who have an LVEF, are in New York Heart Association functional class I with chronic optimal medical therapy, and have a reasonable expectation of survival with good functional status for more than one year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approaches are not useful or may be harmful for the management of asymptomatic LV dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Digitalis in patients with a low LVEF and sinus rhythm, since the risk of harm is not balanced by any known benefit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Use of nutritional supplements to treat structural heart disease or prevent symptomatic heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Calcium channel blockers with negative inotropic activity may be harmful in post-MI patients who have a low LVEF.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2798=[""].join("\n");
var outline_f2_46_2798=null;
var title_f2_46_2799="Fixed effects model";
var content_f2_46_2799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Fixed effects model",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This model assumes there is a single true treatment effect and that all trials provide estimates of this one true effect.",
"    <div class=\"footnotes\">",
"     RD: risk difference; OR: odds ratio; RR: relative risk.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Joseph Lau, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_46_2799=[""].join("\n");
var outline_f2_46_2799=null;
